# NON-INTERVENTIONAL (NI) STUDY PROTOCOL

#### **Study information**

Title	Post-Approval Observational Cohort Study to Evaluate the Safety of the COMIRNATY 2023-2024 Formula in the United States		
Protocol number	C4591062		
Protocol version identifier	1.0		
Date	12 December 2023		
EU Post	To be determined		
Authorization Study			
(PAS) register			
number			
Active substance	COVID-19 Vaccine, mRNA		
Medicinal product	COMIRNATY 2023-2024 Formula		
Research question and objectives	Research question: What is the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula in the United States?		
	Phase 1		
	<ul> <li>Primary objective:</li> <li>To estimate the incidence of pre-specified safety events of interest following vaccination with the COMIRNATY 2023-2024 Formula compared to the incidence of these events during a control window (i.e., expected rates of these events).</li> </ul>		
	Phase 2		
	<ul> <li>Primary objective:</li> <li>To estimate the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula compared to individuals with no recorded vaccination with the COMIRNATY 2023-2024 Formula.</li> </ul>		
	<ul> <li>Secondary objective:</li> <li>To estimate the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula compared to individuals with no recorded vaccination with the COMIRNATY 2023-2024 Formula among subgroups of individuals with concomitant administration of a non-COVID-19 vaccine; immunocompromised individuals; individuals with specific comorbidities; individuals with prior SARS-CoV-2 infection; individuals with prior COVID-19</li> </ul>		

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 1 of 148

	· · · · · · · · · · · · · · · · · · ·
	vaccination; pregnant women; pediatric subjects; and the elderly,
	if sample size permits.
Authors	Jenny Sun, PhD
	Safety Surveillance Research
	Pfizer Inc.
	(617) 417-9453
	jenny.sun@pfizer.com
	Laura E. Dodge, ScD
	Senior Enidemiologist
	Ontum Enidemiology
	(952) 687-3608
	laura dodge@ontum.com
	Florence T. Wang, ScD
	Vice President, Epidemiology
	Optum Epidemiology
	(617) 530-2283
	florence.wang@optum.com
This document contains cor	ifidential information belonging to Pfizer. Except as otherwise agreed to in writing,
by accepting or reviewing t	his document, you agree to hold this information in confidence and not copy or
disclose it to others (except	where required by applicable law) or use it for unauthorized purposes. In the event
of any actual or suspected b	breach of this obligation, Pfizer must be promptly notified.

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 2 of 148

# **1. TABLE OF CONTENTS**

1. TABLE OF CONTENTS	3
2. LIST OF ABBREVIATIONS	5
3. RESPONSIBLE PARTIES	7
4. ABSTRACT	8
5. AMENDMENTS AND UPDATES	12
6. MILESTONES	13
7. RATIONALE AND BACKGROUND	14
8. RESEARCH QUESTION AND OBJECTIVES	15
8.1. Phase 1	15
8.1.1. Primary Objective:	15
8.2. Phase 2	15
8.2.1. Primary Objective:	15
8.2.2. Secondary Objective:	15
9. RESEARCH METHODS	16
9.1. Study Design	16
9.1.1. SCRI	16
9.1.2. Cohort Design	17
9.2. Setting	17
9.2.1. SCRI	18
9.2.2. Cohort Study	19
9.2.3. Vaccination Date and Cohort Entry Date	19
9.2.4. Baseline Period	20
9.2.5. Follow-Up Period	20
9.3. Variables	21
9.3.1. Exposures	21
9.3.2. Outcomes	22
9.3.3. Covariates	24
9.4. Data Sources	26
9.4.1. Optum Pre-Adjudicated Claims Database	26
9.4.2. Optum Research Database	27

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 3 of 148

9.5. Study Size	27
9.6. Data Management	27
9.7. Data Analysis	28
9.7.1. SCRI	28
9.7.2. Cohort Study	28
9.8. Quality Control	30
9.9. Limitations of the Research Methods	31
9.10. Other Aspects	32
10. PROTECTION OF HUMAN PARTICIPANTS	32
10.1. Patient Information	32
10.2. Patient Consent	32
10.3. Institutional Review Board (IRB)/Ethics Committee (EC)	32
10.4. Ethical Conduct of the Study	33
11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS	33
12. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULT	S33
13. REFERENCES	34
14. LIST OF TABLES	41
15. LIST OF FIGURES	41
ANNEX 1. LIST OF STANDALONE DOCUMENTS	42
ANNEX 2. CODE LISTS	43
Appendix I – COMIRNATY 2023-2024 Formula	43
Appendix II – Comparator Codes	44
Appendix III – Safety Outcomes of Interest	49
Appendix IV – Covariate Codes	67
ANNEX 3. ADDITIONAL INFORMATION	148

## 2. LIST OF ABBREVIATIONS

Abbreviation	Definition
ADEM	Acute disseminated encephalomyelitis
AE	Adverse event
AMA	American Medical Association
ASD	Atrial septal defect
AVSD	Atrioventricular septal defect
BEST	Biologics Effectiveness and Safety
CBER	Center for Biologics Evaluation and Research
CDC	Centers for Disease Control and Prevention
CHD	Congenital heart disease
CMS	Centers for Medicare and Medicaid Services
CI	Confidence interval
CIOMS	Council for International Organizations of Medical Sciences
COPD	Chronic obstructive pulmonary disease
COVID-19	Coronavirus disease 2019
СРТ	Current Procedural Terminology
CVST	Cerebral venous sinus thrombosis
EC	Ethics committee
ED	Emergency department
EMA	European Medicines Agency
ENCePP	European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
FDA	Food and Drug Administration
GPP	Good pharmacoepidemiology practices
HCPCS	Healthcare Common Procedure Coding System
HIV	Human deficiency virus
ICD-10	International Classification of Diseases, 10th Revision
ICD-10-CM	International Classification of Diseases, 10th Revision, Clinical Modification
IIS	Immunization Information Systems
IRB	Institutional Review Board
IP	Inpatient
LMP	Last menstrual period
MI	Myocardial infarction
mRNA	Messenger RNA
MS	Multiple sclerosis
NDC	National Drug Code
NSTEMI	Non-ST elevation myocardial infarction
ORD	Optum Research Database
OP	Outpatient
PAS	Post Authorization Study
PASS	Post-authorization safety studies

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 5 of 148 COVID-19 Vaccine 2023-2024 Formula C4591062 NON-INTERVENTIONAL STUDY PROTOCOL Version 1.0, 12 December 2023

Abbreviation	Definition
PDA	Patent ductus arteriosus
PE	Pulmonary embolism
PS	Propensity score
RSV	Respiratory syncytial virus
SAP	Statistical analysis plan
SCRI	Self-controlled risk interval
SOP	Standard operating procedure
STEMI	ST elevation myocardial infarction
TAPVR	Total anomalous pulmonary venous return
US	United States
VAERS	Vaccine Adverse Event Reporting System
VSD	Ventricular septal defect

#### **3. RESPONSIBLE PARTIES**

#### **Principal Investigator(s) of the Protocol**

Name, Degree(s)	Job Title	Affiliation	Address
Jenny Sun, PhD	Safety Surveillance Pfizer Inc. 66 Hudson Blvd		66 Hudson Blvd
	<b>Research Scientist</b>		New York, NY 10001
Laura E. Dodge,	Senior	Optum	1325 Boylston Street
ScD	Epidemiologist,	Epidemiology	Boston, MA 02215
	Epidemiology		
Florence T. Wang,	Vice President,	Optum	1325 Boylston Street
ScD	Epidemiology	Epidemiology	Boston, MA 02215

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 7 of 148

## 4. ABSTRACT

**Title**: Post-Approval Observational Cohort Study to Evaluate the Safety of the COMIRNATY 2023-2024 Formula in the United States

#### Version: 1.0

Date: 12 December 2023

Authors: Optum: Laura E. Dodge, ScD, Senior Epidemiologist, Epidemiology; Florence T. Wang, ScD, Vice President, Epidemiology; Pfizer: Jenny Sun, PhD, Associate Director, Epidemiology, Safety Surveillance Research

**Rationale and background**: In September 2023, the FDA authorized the COMIRNATY 2023-2024 Formula, a monovalent mRNA vaccine targeting the Omicron variant XBB.1.5. More information is needed on whether the safety profile of the COMIRNATY 2023-2024 Formula remains consistent with the safety profile of the original formula in the overall population and in subpopulations of interest.

This non-interventional study is designated as a post-authorization safety study (PASS) and is a condition of authorization to the FDA.

## **Research question and objectives:**

Research question: What is the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula in the United States?

# Phase 1

Primary objective:

• To estimate the incidence of pre-specified safety events of interest following vaccination with the COMIRNATY 2023-2024 Formula compared to the incidence of these events during a control window (i.e., expected rates of these events).

# Phase 2

Primary objective:

• To estimate the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula compared to individuals with no recorded vaccination with the COMIRNATY 2023-2024 Formula.

Secondary objective:

• To estimate the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula compared to individuals with no recorded vaccination with the COMIRNATY 2023-2024 Formula among subgroups of individuals with concomitant administration of a non-COVID-19 vaccine; immunocompromised individuals; individuals with specific comorbidities; individuals

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 8 of 148 with prior SARS-CoV-2 infection; individuals with prior COVID-19 vaccination; pregnant women; pediatric subjects; and the elderly, if sample size permits.

**Study design**: This is a non-interventional observational study utilizing an administrative claims database in the US. Phase 1 will utilize a self-controlled risk interval (SCRI) design, and Phase 2 will utilize a matched comparative safety cohort design.

**Population**: The source population for this study will consist of all individuals with at least one medical or pharmacy claim from 01 September 2023 through 31 March 2024. In Phase 1, individuals age  $\geq 6$  months will be eligible for inclusion if they receive at least one dose of the COMIRNATY 2023-2024 Formula from the date of product launch through 31 March 2024, have continuous medical and pharmacy insurance coverage in the 365 days prior to their vaccination date, experience a safety outcome of interest during a risk or control period, and do not experience the safety event of interest during the clean period prior to vaccination. In Phase 2, individuals age  $\geq 6$  months will be eligible for inclusion in the exposed cohort if they receive a dose of the COMIRNATY 2023-2024 Formula and have continuous medical and pharmacy insurance coverage in the 365 days prior to their vaccination. Individuals age  $\geq$  6 months will be eligible for inclusion in the unexposed cohort if they do not receive a dose of the COMIRNATY 2023-2024 Formula but do have a healthcare encounter and if they have continuous medical and pharmacy insurance coverage in the 365 days prior to their healthcare encounter. Individuals in the unexposed cohort will be matched to those in the exposed cohort if their healthcare encounter is in the same 14-day calendar period as the exposed individual's vaccination date and if they are in the same age group.

# Variables:

- *Exposures*: Exposure to the COMIRNATY 2023-2024 Formula will be defined by the presence of National Drug Codes (NDC) on pharmacy claims or Healthcare Common Procedure Coding System (HCPCS) codes on medical claims.
- *Outcomes*: The pre-specified safety outcomes of interest include the following: acute disseminated encephalomyelitis (ADEM), anaphylaxis, Bell's palsy, cerebral venous sinus thrombosis (CVST), convulsions/seizures (non-febrile), encephalomyelitis, glomerulonephritis, Guillain-Barré syndrome, herpes zoster, immune-mediated myositis, immune thrombocytopenia, Kawasaki disease, multi inflammatory syndrome (in children and adults), multiple sclerosis (MS), myocardial infarction (MI), myocarditis/pericarditis, pulmonary embolism (PE), hemorrhagic stroke, ischemic stroke, and transverse myelitis. Study outcomes will be identified through claims indicators using published validated claims-based algorithms with high performance when available.
- *Covariates*: Baseline covariates will include information related to patient demographics, comorbidities, COVID-19 vaccination, healthcare utilization, and medication history. Additional baseline covariates will be identified on an empiric basis by examining the most frequently occurring diagnoses, drugs dispensed, and procedures performed among

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 9 of 148 individuals with and without COMIRNATY 2023-2024 Formula exposure. Demographic attributes will be determined on the vaccination/cohort entry date, while other factors will be assessed using all available data prior to the vaccination date or cohort entry date.

**Data sources**: The patients included in this study will be drawn from the Optum preadjudicated claims database for the interim report and from the Optum Research Database (ORD) for the final reporting. The pre-adjudicated medical claims, which are supplemented with adjudicated pharmacy claims and health plan enrollment information, encompass hospital and physician claims that are submitted and processed daily from a large US commercial health plan. The individuals included in the pre-adjudicated medical claims database are fully insured by the health plan, which provides reimbursement of medical and pharmacy services regardless of site of care, and individuals are geographically diverse within the US. The ORD is a proprietary research database containing eligibility and adjudicated pharmacy and medical claims data from a large US health plan affiliated with Optum. In 2021, data were available for approximately 12.6 million individuals with medical and pharmacy coverage.

**Study size**: The sample size achieved will depend on the number of recipients of the COMIRNATY 2023-2024 Formula in the databases. All individuals who meet the study's eligibility criteria during the study period will be included.

#### Data analysis:

*Phase 1*: For the SCRI design, the observed incidence rates of the pre-specified safety outcomes of interest will be estimated in the risk window and the control window. Among individuals who experience an outcome of interest, an exact conditional Poisson regression model with the natural logarithm of the person-time as the offset will be used to calculate the rate ratio and corresponding 95% confidence interval (CI) of events occurring during the risk period relative to the control period. The results from the SCRI utilizing the Optum pre-adjudicated claims database will be presented in the interim report, while results utilizing the ORD will be presented in the final report.

*Phase 2*: In the cohort study, propensity score matched cohorts of COMIRNATY 2023-2024 Formula-vaccinated patients and comparator patients with no recorded dose of the COMIRNATY 2023-2024 Formula will be created. Following the application of outcomespecific exclusions, the incidence rate of each safety outcome will be estimated among the COMIRNATY 2023-2024 Formula-exposed group and its matched comparator group. The rate ratio will be estimated using unconditional Poisson regression. Secondary analyses will be conducted among individuals receiving concomitant non-COVID-19 vaccines; immunocompromised individuals; individuals with specific baseline comorbidities; individuals with prior SARS-CoV-2 infection; individuals with prior COVID-19 vaccination; pregnant women; individuals aged  $\leq$  18 years; and individuals aged  $\geq$  65 years. Lastly, a descriptive analysis of the matched cohorts will focus specifically on outcomes related to pregnancy (spontaneous abortion, stillbirth, preterm birth, major congenital malformations and small for gestational age).

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 10 of 148 **Milestones**: Planned start of data collection is 15 January 2024. Planned completion date for the interim report is 30 June 2024. The planned end of data collection is 31 August 2025, and the planned completion date for the final report is 30 April 2026.

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 11 of 148

#### **5. AMENDMENTS AND UPDATES**

None.

#### 6. MILESTONES

Milestone	Planned Date
Final study protocol	31 March 2024
Registration in the EU PAS register	To be determined
Start of data collection <sup>a</sup>	15 January 2024
Interim report <sup>b</sup>	30 June 2024
End of data collection <sup>c, d</sup>	31 August 2025
Final study report <sup>d</sup>	30 April 2026

a For studies with secondary data collection, the start of data collection is defined as the planned date for starting data extraction for the purposes of the interim analysis.

b The milestone date was chosen to inform decision making for the next adapted vaccine before Fall 2024. To meet this milestone, the data extraction for the interim reporting will include data through 15 January 2024.

c For studies with secondary data collection, the end of data collection is defined as the planned date on which the analytical dataset will be first completely available; the analytic dataset is the minimum set of data required to perform the statistical analysis for the final reporting.

d The sponsor may extend the study period. This revision, if needed, will be communicated to the FDA as a protocol amendment. Details on this contingency plan are provided in Section 9.2.

# 7. RATIONALE AND BACKGROUND

The development of vaccines against SARS-CoV-2 has been critical to ending the Coronavirus disease 2019 (COVID-19) pandemic. In the United States (US), the first to become available were the messenger RNA (mRNA) vaccines BNT162B2 (COMIRNATY) (Pfizer Inc/BioNTech, 2023) and mRNA-1273 (Moderna US, Inc., 2023). Authorized for emergency use by the US Food and Drug Administration (FDA) on 11 December 2020 and 18 December 2020, respectively, these first-generation vaccines contained a piece of the original SARS-CoV-2 virus's mRNA, instructing cells in the body to make the virus's distinctive "spike" protein and triggering an immune response (FDA, 2020a, 2020b; Nabizadeh et al., 2023). Beginning in August 2022, in response to the new circulating Omicron variant of SARS-CoV-2, the vaccines were adapted to add an mRNA component from the Omicron lineages BA.4 and BA.5, in addition to mRNA from the original viral strain, and were thereafter referred to as bivalent vaccines (FDA, 2022b, 2022c, 2022d). Most recently, in September 2023, the COMIRNATY 2023-2024 Formula was approved for individuals  $\geq$  12 years of age. The Pfizer-BioNTech COVID-19 Vaccine 2023-2024 Formula is currently authorized under emergency use in individuals 6 months through 11 years of age. This new formulation contains a monovalent (single) mRNA component corresponding to the Omicron variant XBB.1.5 (FDA, 2023b). The Omicron XBB sublineage accounted for nearly all COVID-19 cases in the US in spring 2023 and remained the most common variant as of 08 July 2023 (CDC, 2020).

Based on data from the original COMIRNATY formula, the US prescribing information for COMIRNATY highlights the following warnings and precautions:

- "Postmarketing data demonstrate increased risks of myocarditis and pericarditis"
- "Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY." (Pfizer Inc/BioNTech, 2023)

Additionally, the following serious adverse events have been observed after immunization with the Pfizer-BioNTech, Moderna, and Janssen vaccines as reported in the Vaccine Adverse Event Reporting System (VAERS): glomerulonephritis, herpes zoster, immunemediated myositis, and relapsing or progressing MS (*VAERS*, 2023). More information is needed on whether the safety profile of the COMIRNATY 2023-2024 Formula remains consistent with the safety profile of the original formula in the overall population and subpopulations of interest.

Pfizer/BioNTech, sponsor of the first COVID-19 vaccine to be authorized in the US, is conducting a non-interventional PASS to collect information on the safety profile of its most recently authorized strain of the COVID-19 vaccine, the Omicron XBB.1.5 monovalent vaccine (COMIRNATY 2023-2024 Formula; Pfizer Inc/BioNTech, 2023). This combined protocol and statistical analysis plan (SAP) describes a non-interventional observational study using claims data from a large US insurer to evaluate the safety of the COMIRNATY 2023-2024 Formula in the general population as well as in subpopulations of interest. This

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 14 of 148 non-interventional study is designated as a PASS and is a condition of authorization to the FDA.

# 8. RESEARCH QUESTION AND OBJECTIVES

The research question of this study is: What is the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula in the United States? To answer this question, the study will be conducted in two phases, each with its own specific objectives.

# 8.1. Phase 1

Phase 1 will be designed to sequentially monitor the occurrence of pre-specified safety events of interest following vaccination.

## 8.1.1. Primary Objective:

• To estimate the incidence of pre-specified safety events of interest following vaccination with the COMIRNATY 2023-2024 Formula compared to the incidence of these events during a control window (i.e., expected rates of these events).

# 8.2. Phase 2

Phase 2 will be designed to assess the risk of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula compared to individuals with no recorded vaccination for the COMIRNATY 2023-2024 Formula for up to 1 year after vaccination.

# 8.2.1. Primary Objective:

• To estimate the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula compared to individuals with no recorded vaccination for the COMIRNATY 2023-2024 Formula.

# 8.2.2. Secondary Objective:

• To estimate the incidence of pre-specified safety events of interest among individuals who receive the COMIRNATY 2023-2024 Formula compared to individuals with no recorded vaccination with the COMIRNATY 2023-2024 Formula among subgroups of individuals with concomitant administration of a non-COVID-19 vaccine; immunocompromised individuals; individuals with specific comorbidities; individuals with prior SARS-CoV-2 infection; individuals with prior COVID-19 vaccination; pregnant women; pediatric subjects; and the elderly, if sample size permits.

## 9. RESEARCH METHODS

## 9.1. Study Design

This non-interventional study will be conducted in two phases. Phase 1 will include a study of self-controlled risk interval (SCRI) design conducted using a pre-adjudicated claims database for the interim report. For the final report, the SCRI study will be repeated using the ORD, an adjudicated claims database. Phase 2 will be a comparative safety cohort design using the ORD and will also be included in the final report.

Table 1 summarizes the study designs and data sources included in the interim and final reports. These two different study designs are complimentary, each with its own strengths. The SCRI design is less impacted by misclassification of COVID-19 vaccine exposure and confounding by time-fixed characteristics, while the cohort study design enables a longer follow-up period.

	Interim Report	Final Report
Study Design	SCRI (Section 9.1.1)	SCRI (Section 9.1.1) Cohort (Section 9.1.2)
Data Source	Optum pre-adjudicated claims database (Section 9.4.1)	ORD (adjudicated) database (Section 9.4.2)

 Table 1.
 Study design and data sources for interim and final reporting

# 9.1.1. SCRI

Phase 1 will monitor the incidence rate of pre-specified safety events of interest in a general population of individuals who receive the COMIRNATY 2023-2024 Formula using an SCRI study design that tracks post-vaccination risk intervals and control (reference) periods for each vaccinated individual. Monitoring will be conducted during a pre-specified risk period immediately following vaccination, and the observed rate of events during this risk period will be compared to that of a control period temporally removed from the vaccination event. As depicted in Figure 1, only individuals who receive the COMIRNATY 2023-2024 Formula will be included in the SCRI study (Baker et al., 2015). Within each individual, outcomes occurring during the risk interval will be compared with those occurring during the control period, in order to determine whether these outcomes occur more frequently immediately after vaccination as compared with a reference period. A washout period may be inserted between the risk interval and the control period to ensure that events relating to the vaccine are not incorrectly attributed to the control period. To ensure that observed outcomes are truly incident, a period free from the outcome of interest (clean period) may be required prior to vaccination.



Figure 1. Self-controlled risk interval design

Certain individuals (i.e., immunocompromised patients aged 6 months through 11 years; FDA, 2023b) may receive more than one dose of the COMIRNATY 2023-2024 Formula and thus may have multiple risk and control periods. For these individuals, analysis may be conducted using the first dose and repeated by pooling the multiple risk periods, as well as the control periods.

The safety outcomes of interest, along with relevant clean windows, risk intervals, and washout and control periods, are listed in Section 9.3.2.

# 9.1.2. Cohort Design

Phase 2 will consist of a matched cohort study of individuals with and without a recorded dose of the COMIRNATY 2023-2024 Formula, conducted within the ORD. Beginning with the day the COMIRNATY 2023-2024 Formula is launched, individuals who receive the COMIRNATY vaccine within a given 14-day calendar period (e.g., 01 September 2023 to 14 September 2023, 15 September 2023 to 28 September 2023) will be matched without replacement to appropriate comparators with no recorded vaccination with the COMIRNATY 2023-2024 Formula but who have a healthcare encounter within the same 14-day calendar period. Matching will also be based on age group (e.g., 6 months–4 years, 5–11 years, 12–17 years, 18–64 years, and  $\geq$  65 years). Alternate calendar periods (e.g., one month) may be empirically explored.

Once exposed and unexposed individuals who have been matched on age group within a given 14-day calendar period have been identified, propensity score (PS) matching will be performed to address control of confounding. Within any given calendar period, comparators will be matched to a COMIRNATY recipient on PS, down to a maximum allowable level of precision in the PS (Section 9.7.2.1). This will ensure a sufficient pool of comparators for stratified and/or subpopulation analyses (Sections 9.7.2.3 & 9.7.2.4).

For this Phase 2 matched cohort study, the safety outcomes of interest are listed in Section 9.3.2.

# 9.2. Setting

The source population for this study will consist of all individuals with at least one medical or pharmacy claim from 01 September 2023 through 31 March 2024. The end date of 31

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 17 of 148 March 2024 was chosen based on the assumption that vaccine uptake will be similar to uptake during the 2022-2023 season. During the 2022-2023 COVID-19 season, the end of March reflected the time when uptake of the bivalent booster was no longer increasing (i.e., most individuals who received the bivalent booster dose had done so prior to March 2023), and COVID-19 cases declined substantially from their peak (CDC, 2020).

Trends in COVID-19 vaccine uptake will be monitored until 30 June 2024 using the Centers for Disease Control and Prevention's (CDC) Weekly COVID-19 Vaccination Dashboard (CDC, 2023d), which publishes estimates of the proportions of children aged 6 months through 17 years and adults 18 years and older who have received a COVID-19 vaccine each week during the 2023-2024 season. If in the final week of reported data for June 2024 these estimates show vaccine uptake in either children or adults that is 1% or greater than the respective estimates reported for the first week of April 2024 (i.e., an increasing trend in COVID-19 vaccine uptake from the first week of April 2024 to the last week of June 2024), then the Sponsor will extend the end date of the accrual period into October 2024, and the updated source population will be reflected in the final study report. This date reflects the latest accrual date that still allows for meeting of the current study milestones. This revision, if needed, will be communicated to the FDA as a protocol amendment.

Each study design will have its own inclusion and exclusion criteria, as listed below.

# 9.2.1. SCRI

## 9.2.1.1. Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in Phase 1 of the study:

- 1. Receive at least one dose of the COMIRNATY 2023-2024 Formula from the date of the COMIRNATY 2023-2024 product launch through 31 March 2024.
- 2. Age  $\geq$  6 months when receiving their first recorded dose of the COMIRNATY 2023-2024 Formula.
- 3. Have continuous medical and pharmacy insurance coverage in the 365 days prior to their vaccination date (as defined in Section 9.2.3), or since birth if the vaccination occurred at <1 year of age.
- 4. Experience a safety outcome of interest during a risk interval or control period (on or after vaccination, as defined in Section 9.3.2).
- 5. Do not experience the safety outcome of interest during the clean period (prior to vaccination, as defined in Section 9.3.2).

# 9.2.1.2. Exclusion Criteria

Patients meeting any of the following criteria will not be included in Phase 1 of the study:

- 1. Are of unknown sex.
- 2. Have a missing month and year of birth.

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 18 of 148

- 3. Have received a COVID-19 vaccine other than the COMIRNATY 2023-2024 Formula in the 270 days prior to the vaccination date (as defined in Section 9.2.3).
- 4. Have received a COVID-19 vaccine other than the COMIRNATY 2023-2024 Formula on the same vaccination date (defined in Section 9.2.3).

# 9.2.2. Cohort Study

# 9.2.2.1. Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in Phase 1 of the study:

- 1. Age  $\geq$  6 months on the day of receiving their first recorded dose of the COMIRNATY 2023-2024 Formula (if a vaccine recipient), or on the day they experience a healthcare encounter (if a comparator), defined as the cohort entry date (Section 9.2.3).
- 2. Have continuous medical and pharmacy insurance coverage in the 365 days prior to the cohort entry date, or since birth if the cohort entry date occurred at < 1 year of age.

# 9.2.2.2. Exclusion Criteria

Patients meeting any of the following criteria will not be included in Phase 2 of the study:

- 1. Are of unknown sex.
- 2. Have a missing month and year of birth.
- 3. Have received a COVID-19 vaccine other than the COMIRNATY 2023-2024 Formula in the 270 days prior to cohort entry date (as defined in Section 9.2.3).
- 4. Have received both the COMIRNATY 2023-2024 Formula and a COVID-19 vaccine other than the COMIRNATY 2023-2024 Formula on the cohort entry date (defined in Section 9.2.3).

In both phases of the study, when creating the analytic population for each specific safety outcome of interest, individuals will be excluded if they experienced that safety outcome during the portion of the baseline period designated as the clean period (Section 9.2.4).

# 9.2.3. Vaccination Date and Cohort Entry Date

In the Phase 1 SCRI analysis, the date of first vaccination with the COMIRNATY 2023-2024 Formula will be set as the vaccination date. For the analysis assessing individuals who receive more than one dose of the COMIRNATY 2023-2024 Formula, each vaccination with the COMIRNATY 2023-2024 Formula will be set as a new vaccination date.

In the Phase 2 cohort analysis, the cohort entry date will be the date individuals in the COMIRNATY group receive their first recorded dose of the COMIRNATY 2023-2024 Formula. From the pool of patients without a recorded dose of COMIRNATY 2023-2024 Formula, matched comparators will be identified based on age and calendar time. Regarding age, matching will be performed between patients within age groups (e.g., 6 months–4 years,

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 19 of 148 5–11 years, 12–17 years, 18–64 years, and  $\geq$  65 years). Regarding calendar time, patients will be matched within 14-day windows (e.g., 01 September 2023 to 14 September 2023, 15 September 2023 to 28 September 2023) in which individuals in the exposed cohort will have received vaccination with the COMIRNATY 2023-2024 Formula and individuals in the unexposed cohort will have had a healthcare encounter but no recorded vaccination with the COMIRNATY 2023-2024 Formula. Alternate calendar periods (e.g., one month) may be empirically explored.

For matched comparators, the cohort entry date will be the date within the matched 14-day calendar period on which they had a healthcare encounter.

# 9.2.4. Baseline Period

The baseline period will consist of all continuously enrolled available time up to 3 years prior to the vaccination date (SCRI) or cohort entry date (cohort study). Recognizing that narrower or specific windows of assessment may better capture select patient attributes of interest, specific covariates may be assessed using alternate time period(s). In this study, all individuals are required to have a minimum of 365 days of continuous health plan enrollment prior to the vaccination or cohort entry date (Sections 9.2.1.1 and 9.2.2.1), or continuous enrollment since birth if the vaccination or cohort entry date occurred at < 1 year of age.

In both study designs, some or all of the baseline period will be used to exclude individuals with prevalent outcomes prior to vaccination or cohort entry date. This portion of the baseline period will be referred to as the 'clean period.' For a list of outcome-specific clean periods, please see Section 9.3.2.

# 9.2.5. Follow-Up Period

# 9.2.5.1. SCRI

In the SCRI analysis, follow-up for the risk period will begin upon (for the outcomes of anaphylaxis and convulsions/seizures) or one day after (for all other outcomes) receipt of the COMIRNATY 2023-2024 Formula (Table 2) and continue until the earliest of:

- Receipt of a COVID-19 vaccine other than the COMIRNATY 2023-2024 Formula;
- The end of the outcome-specific risk interval as defined in Section 9.3.2;
- Disenrollment from the health plan, death, or the end of data collection.

After the outcome-specific pre-specified washout period following the risk interval, followup for the control period will begin and continue until the earliest of:

- Receipt of a COVID-19 vaccine other than the COMIRNATY 2023-2024 Formula;
- The end of the control period as defined in Section 9.3.2;

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 20 of 148 • Disenrollment from the health plan, death, or the end of data collection.

Individuals will be followed for each safety outcome during both the risk and control periods, such that events observed during the risk period or washout period will not censor follow-up for the control period.

# 9.2.5.2. Cohort Study

In the cohort study (Phase 2), depending on the safety outcome of interest, follow-up will begin on cohort entry or the day following cohort entry (Table 2) and extend until the earliest of:

- The occurrence of an outcome of interest (Section 9.3.2);
- Receipt of a COVID-19 vaccine other than the COMIRNATY 2023-2024 Formula;
- The end of the outcome-specific risk interval as defined in Table 2;
- Disenrollment from the health plan, death, or the end of data collection;
- For comparators who later receive a dose of the COMIRNATY 2023-2024 Formula, the date of vaccination with COMIRNATY.

Those comparators who later receive a dose of COMIRNATY 2023-2024 Formula may be eligible for inclusion in the COMIRNATY 2023-2024 Formula cohort if they meet the eligibility criteria for cohort entry.

# 9.3. Variables

# 9.3.1. Exposures

# 9.3.1.1. COMIRNATY 2023-2024 Formula

The SCRI analysis and the cohort analysis will include individuals with exposure to the COMIRNATY 2023-2024 Formula. The code list to define exposure is available in Annex 2 (Appendix I).

# 9.3.1.2. Comparator Cohort

The Phase 2 cohort study will include comparators with no recorded vaccination for the COMIRNATY 2023-2024 Formula. To improve comparability with the COMIRNATY 2023-2024 Formula vaccinated cohort, patients included in the comparator cohort will be required to have a code indicative of a healthcare encounter, including one of the following:

- Presence of a code for a vaccine other than the COMIRNATY 2023-2024 Formula;
- Presence of a code indicative of an outpatient healthcare encounter.

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 21 of 148 Codes relating to other vaccines or outpatient visits are provided in Annex 2 (Appendix II).

# 9.3.2. Outcomes

In both the SCRI and cohort studies, the pre-specified safety outcomes of interest will include the following:

- ADEM
- Anaphylaxis
- Bell's palsy
- CVST
- Convulsions/seizures (non-febrile)
- Encephalomyelitis
- Glomerulonephritis
- Guillain-Barré syndrome
- Herpes zoster
- Immune-mediated myositis
- Immune thrombocytopenia
- Kawasaki disease
- Multi inflammatory syndrome (in children and adults)
- MS
- MI
- Myocarditis/pericarditis
- PE
- Stroke, hemorrhagic
- Stroke, ischemic
- Transverse myelitis

In addition, in Phase 2 of the study, the following pregnancy outcomes will be assessed in pregnant women or their infants, if sample size permits:

- Spontaneous abortion
- Stillbirth
- Preterm birth
- Major congenital malformations

# PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 22 of 148 • Small for gestational age

Code lists for the safety outcomes of interest are provided in Annex 2 (Appendix III). Corresponding site of care requirements are listed in Table 2. When possible, outcomes will be defined using a validated claims-based algorithm with high performance (CBER, 2021).

If a safety signal is detected in the interim report, then medical records will be retrieved for a subset of participants to confirm the presence of that study outcome. A safety signal that requires confirmation through medical record review will be defined as a rate ratio of > 3.0 and a corresponding P value of < 0.01 in the primary analysis of the SCRI design (details in Section 9.7.1.1).

Outcome	Clean Period*	Vaccine Risk	Care Setting**
		Interval*	
Acute disseminated	Days -28 to -1	Days 1 to 21	IP
encephalomyelitis			
Anaphylaxis	Days -30 to -1	Days 0 to 1	IP, ED
Bell's palsy	Days -183 to -1	Days 1 to 42	IP, OP
Cerebral venous sinus thrombosis	Days -365 to -1	Days 1 to 28	IP, OP
Convulsions/seizures, non-febrile	Days -42 to -1	Days 0 to 21	IP, OP
Encephalomyelitis	Days -183 to -1	Days 1 to 42	IP
Glomerulonephritis	Days -365 to -	Days 1 to 42***	IP, OP
	1***		
Guillain-Barré syndrome	Days -365 to -1	Days 1 to 42	IP-primary
			position only
Herpes zoster	Days -270 to -1	Days 1 to 30	IP, OP
Immune-mediated myositis	Days -365 to -	Days 1 to 28	IP, OP
	1***		
Immune thrombocytopenia	Days -365 to -1	Days 1 to 42	IP, OP
Kawasaki disease	Days -365 to -1	Days 1 to 21	IP, OP
Multi inflammatory syndrome	Days -365 to -1	Days 1 to 42	IP, ED
Multiple sclerosis	All available	Days 1 to 42***	IP, OP
Myocardial infarction	Days -365 to -1	Days 1 to 28	IP
Myocarditis/pericarditis	Days -365 to -1	Days 1 to 21	IP, OP
Pulmonary embolism	Days -365 to -1	Days 1 to 28	IP, OP
Stroke, hemorrhagic	Days -365 to -1	Days 1 to 28	IP
Stroke, ischemic	Days -365 to -1	Days 1 to 28	IP
Transverse myelitis	Days -365 to -1	Days 1 to 42	IP, ED

 Table 2.
 Clean periods and risk intervals for safety outcomes of interest

\*Expressed in relation to the day of vaccination or cohort entry (Day 0). When more than one vaccine risk interval had been cited in the prior literature, the present risk interval was chosen from the prior literature using the following order of priority for all outcomes other than myocarditis/pericarditis: 1) CBER 2021; 2) the most frequently cited risk interval in prior literature; and 3) the shortest risk interval cited in prior literature. The risk interval for myocarditis/pericarditis was chosen based on CBER 2022.

\*\*IP, Inpatient; ED, Emergency department visit; OP, Outpatient facility claims and professional/provider claims.

\*\*\*Could not be determined from the literature, so modeled after other outcome intervals in CBER 2021.

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023

# 9.3.2.1. Outcome-Specific Risk and Control Periods

The SCRI design (Section 9.1.1) requires that clean periods, risk intervals, washout periods, and control intervals be specified for every study outcome. The lengths of the clean periods and risk intervals are listed in Table 2. The washout period for all outcomes will begin immediately after the end of the risk interval and continue for 30 days (Akpandak et al., 2022); the control period will follow the washout period and be equivalent in length to the risk interval. Interval lengths were determined based on prior vaccine literature, including COVID-19 vaccine studies conducted as part of the FDA's Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) System (Akpandak et al., 2022; Barda et al., 2021; CBER, 2021; Joy et al., 2023; Klein et al., 2021; Liu et al., 2023; Martin et al., 2021; McCarthy et al., 2013; Wack et al., 2021).

## 9.3.3. Covariates

All members of the study cohorts will be described according to covariates identified in the claims data. Demographic attributes will be determined on the vaccination/cohort entry date, while other factors will be assessed using all available data prior to the cohort entry date unless otherwise specified. Unless specified as for descriptive purposes only, the covariates listed will be included in the PS models.

## **Demographic Attributes**

- Sex
- Age; for the purposes of matching the exposed and unexposed cohorts in Phase 2, we will use the following age groups: 6 months–4 years, 5–11 years, 12–17 years, 18–64 years, and ≥ 65 years
- Calendar month of the vaccination date or cohort entry date
- Geographic region

# Comorbidities

- Asthma
- Non-malignant blood disorders, including sickle cell disease
- Chronic lung disease, including chronic obstructive pulmonary disease (COPD)
- Down syndrome
- Heart disease
- History of SARS-CoV-2 infection
- Immunocompromised status (i.e., history of human deficiency virus [HIV]; organ, bone marrow or stem cell transplant; use of immunosuppressant medication)
- Kidney disorders, including chronic kidney disease
- Liver disorders
- Neurological or neurodevelopmental conditions
- Malignant neoplasms

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 24 of 148

- Obesity
- Type 2 diabetes

# **Prior COVID-19 Vaccination**

- Number of COVID-19 vaccine doses (any brand) prior to 2023-2024
- Days from the most recent prior COVID-19 vaccine dose (any brand) to first vaccination with 2023-2024 formulations (for all Phase 1 individuals, as well as Phase 2 individuals receiving COMIRNATY or another 2023-2024 formulation)

# **Healthcare Utilization**

- Number of hospitalizations in prior year
- Number of emergency room visits in prior year
- Number of outpatient encounters in prior year
- Other recorded vaccines administered
  - Seasonal influenza
  - o RSV

# **Medication History**

- Systemic immunomodulators
- Corticosteroids
- Antivirals
- Antibiotics

In addition to the covariates listed above, baseline attributes will be identified on an empiric basis by examining the most frequently occurring diagnoses, drugs dispensed, and procedures performed among individuals with and without COMIRNATY 2023-2024 Formula exposure. These empiric covariates will be considered for inclusion in the PS models if they are potential confounders.

# COVID-19 Vaccination – Descriptive only (not for inclusion in PS model)

- Site of vaccination (e.g., outpatient, pharmacy)
- Source of vaccination information (e.g., CPT code<sup>1</sup>, NDC)
- Number of doses prior to 2023-2024, by year and vaccine product

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 25 of 148

<sup>&</sup>lt;sup>1</sup> CPT copyright 2022 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

• Average number of days between doses of COMIRNATY 2023-2024 Formula, among those with multiple doses

Code lists for covariates are included in Appendix IV.

# 9.4. Data Sources

The patients included in this study will be drawn from the Optum pre-adjudicated claims database for the interim reporting to expedite the identification of vaccinated patients, and from the ORD for the final reporting. These data sources are described below.

# 9.4.1. Optum Pre-Adjudicated Claims Database

The database includes pre-adjudicated medical claims, supplemented with adjudicated pharmacy claims and health plan enrollment information. As claims for pharmacy services are typically submitted electronically by the pharmacy at the time prescriptions are filled or vaccinations are administered and are updated in the underlying database on a weekly basis, they are not included in the pre-adjudicated feed. The pre-adjudicated medical claims encompass hospital and physician claims that are submitted and processed daily from a large US commercial health plan. The individuals included in the pre-adjudicated medical claims database are fully insured by the health plan, which provides reimbursement of medical and pharmacy services regardless of site of care, and individuals are geographically diverse within the US. The claims adjudication process involves numerous assessments and adjustments and may result in claims being returned to the provider for revision or sent for payment processing. The pre-adjudicated claims are maintained in a database that allows for the capture of up to three years of prior data. These pre-adjudicated claims have been used for research previously, and for federally funded public health surveillance (Dore et al., 2012; FDA, 2021b; Shoaibi et al., 2023; Wong et al., 2023; Moll et al., 2023; Schneider et al., 2023).

The data include demographics, details from pharmacy claims (reflecting dispensings), and all pre-adjudicated medical and facility claims, including information on the types of services or procedures and their accompanying diagnoses. The coding of medical claims conforms to insurance industry standards, including:

- Use of designated claims forms (e.g., physicians use the CMS-1500 format and hospitals use the UB-04 format)
- International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis codes and procedure codes
- Current Procedural Terminology (CPT-4®)<sup>2</sup> codes
- Centers for Medicare and Medicaid Services (CMS) HCPCS codes

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 26 of 148

<sup>&</sup>lt;sup>2</sup> CPT copyright 2022 American Medical Association. All rights reserved.

Claims for pharmacy services are typically submitted electronically by the pharmacy at the time prescriptions are filled. These data allow for longitudinal tracking of medication refill patterns and changes in medications and include:

- NDC
- Drug name
- Dosage form
- Drug strength
- Fill date
- Days of supply
- Cost information
- De-identified patient and prescriber codes

# 9.4.2. Optum Research Database

The ORD is a proprietary research database containing eligibility and adjudicated pharmacy and medical claims data from a large US health plan affiliated with Optum. The individuals covered by this health plan are geographically diverse across the US. As early as 1993, medical and pharmacy claims data are available for 70 million individuals with both medical and pharmacy benefit coverage. In 2021, data were available for approximately 12.6 million individuals with medical and pharmacy coverage. Optum research activities use de-identified data from the research database. In limited instances, patient identifiers may be accessed where applicable law allows the use of patient-identifiable data, and when the study obtains appropriate approvals for accessing data that are not de-identified.

# 9.5. Study Size

The sample size achieved will depend on the number of recipients of the COMIRNATY 2023-2024 Formula in the databases. All individuals who meet the study's eligibility criteria during the study period will be included.

# 9.6. Data Management

All analyses will be conducted using Statistical Analysis System (SAS) version 9.4 (SAS Institute Inc., Cary, North Carolina) and SAS Enterprise Guide 6.1 or later. The data will be extracted once per report. All reports will utilize the structured data only. The interim report will include summarized results from the Optum pre-adjudicated claims database described in Section 9.4.1. The final report will include results summarized from the ORD as described in Section 9.4.2. The characteristics of patients to be included in each data extract (e.g., required vaccine codes) and the specific timeframes of each data extract will reflect the study inclusion/exclusion criteria described in Section 9.2, the baseline and follow-up periods in Sections 9.2.4 and 9.2.5, and the study variables in Section 9.3. All reports and deliverables will contain aggregated results only and will not identify individual patients, physicians, or facilities.

#### 9.7. Data Analysis

## 9.7.1. SCRI

## 9.7.1.1. Primary Analysis

Descriptive statistics will be used to summarize the baseline characteristics of those who receive the COMIRNATY 2023-2024 Formula. Counts of each safety outcome of interest will be reported within pre-specified risk and control windows. Then, the observed incidence rates of the outcomes of interest will be estimated in the risk window and the control window. Among the individuals who experience an outcome of interest, an exact conditional Poisson regression model with the natural logarithm of the person-time as the offset will be used to calculate the relative incidence (rate ratio) and corresponding 95% confidence interval (CI) of the risk period relative to the control period. With the self-controlled design, whereby each individual serves as their own comparator, the analysis accounts for the factors that vary across but not within individuals (i.e., time-invariant covariates).

The results from the SCRI utilizing the Optum pre-adjudicated claims database will be presented in the interim report, while results from the SCRI utilizing the ORD will be presented in the final report.

# 9.7.2. Cohort Study

## 9.7.2.1. Propensity Score Modeling and Matching

The COMIRNATY 2023-2024 Formula-exposed and the age- and calendar-period matched comparator cohorts will be created as described in Section 9.2.3. Each cohort member will be described with respect to baseline covariates as listed in Section 9.3.3. These cohort members will be included in the propensity score modelling and matching.

This study will use a single PS model that encompasses risk factors for multiple outcomes, an approach demonstrated in other studies conducted to fulfill post-licensure regulatory commitments and requirements to the FDA and other regulatory agencies (Seeger et al., 2023; Ziyadeh et al., 2020). While not all risk factors may be associated with all outcomes to the same degree, adjusting for covariates that are weakly or not at all associated with a given outcome is expected to result in negligible bias if residual confounding is small (Brookhart et al., 2006; Myers et al., 2011). Incorporating a wide array of outcome predictors (Section 9.3.3) into the PS is expected to minimize residual confounding, producing groups with similar patterns of both measured and unmeasured factors (Guertin et al., 2016).

The PS model will incorporate the pre-specified demographic and comorbidity covariates, healthcare utilization, and calendar period as independent variables, and an indicator for receipt of the COMIRNATY 2023-2024 Formula as the dependent variable. Two-way interactions of all variables with calendar period, or empirically defined variables that are potential confounders, may also be considered for inclusion in the model.

A greedy digit-based matching algorithm will be used, in which patients exposed to the COMIRNATY 2023-2024 Formula are matched without replacement to comparator patients

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 28 of 148 at a given level of precision defined by the number of digits of the PS (Parsons, 2001). When no further matches are available at a given level of precision, the number of digits is sequentially reduced until a maximum allowable caliper of 0.1 is reached, thereby ensuring that the matched cohorts are comparable with respect to the underlying measured risk factors. A matching ratio (e.g., 1:10) may be implemented.

PS matching will produce a single matched cohort (the master cohort) that will be used to conduct all primary, secondary, and sensitivity analyses for the study outcomes. Balance between the PS-matched cohorts will be evaluated by overlaying graphs of the PS distributions in COMIRNATY-exposed and comparator cohorts before and after PS matching. Additionally, standardized differences between the PS-matched cohorts for each covariate in the model will also be assessed. Variables with an absolute standardized difference less than 0.1 will be considered balanced (Austin, 2009). If a variable has a standardized difference that is greater than 0.1, further PS model modifications (e.g., addition of interaction terms) or inclusion of the imbalanced covariates in an outcome model will be considered (Normand et al., 2001). If there are confounders identified that would only be appropriate to include for one outcome and not the others, a separate PS model for the specific outcome will be considered.

Outcome-specific exclusion criteria will be applied to the master cohort after PS matching but before the outcome specific analysis; the matched cohort that remains will be the analytic cohort for that specific outcome. The matched comparators of individuals excluded for outcome-specific exclusion criteria will also be excluded from the outcome-specific analysis.

# 9.7.2.2. Primary Analysis

Once the matched cohorts have been created, the incidence rate of each safety outcome will be estimated among the COMIRNATY 2023-2024 Formula-exposed group and its matched comparator group. The rate ratio will be estimated using unconditional Poisson regression. If standardized differences show covariate imbalances in the matched cohorts, imbalanced covariates will be included in the unconditional Poisson models.

# 9.7.2.3. Secondary Analysis

The main analysis will compare the occurrence of safety outcomes in the COMIRNATY 2023-2024 Formula-exposed group to that of the matched comparator group. Secondary analyses will conduct this comparison separately for various subsets of the matched comparator group, including:

- 1. Comparators who, on cohort entry, received a 2023-2024 formulation of a COVID-19 vaccine other than COMIRNATY (i.e., Moderna or Novavax)
- 2. Comparators who received a non-COVID-19 vaccine on cohort entry
- 3. Comparators who did not receive a vaccine on cohort entry but had another type of outpatient health encounter.

## 9.7.2.4. Subgroup Analysis

If sample size permits, the main analysis will be restricted to the following subgroups:

- Individuals with concomitant administration of a non-COVID-19 vaccine (e.g., seasonal influenza, RSV) on cohort entry date; specific analyses will be performed among individuals receiving seasonal influenza vaccine and those receiving RSV vaccine
- Immunocompromised individuals (Section 17.4.1.7)
- Individuals with specific baseline comorbidities, such as a chronic lung, heart, kidney or liver condition; cancer; Down syndrome or other neurological or neurodevelopmental disorders; and blood disorders (Section 17.4.1)
- Individuals with prior SARS-CoV-2 infection
- Individuals with prior COVID-19 vaccination
- Pregnant women
- Individuals aged  $\leq 18$  years
- Individuals aged  $\geq 65$  years

Lastly, a descriptive analysis of the matched cohorts will focus specifically on outcomes related to pregnancy (spontaneous abortion, stillbirth, preterm birth, major congenital malformations and small for gestational age). Recipients of the COMIRNATY 2023-2024 Formula and comparators who are pregnant at cohort entry will be identified, and the timing of their vaccination in relation to their last menstrual period (LMP) will be characterized. Baseline characteristics will be descriptively compared among the pregnant COMIRNATY 2023-2024 Formula recipients and comparators. Among COMIRNATY 2023-2024 Formula recipients who are pregnant at cohort entry, as well as among pregnant comparators, the incidence of pregnancy outcomes (spontaneous abortion, stillbirth, preterm birth) during follow-up will be described. For those individuals whose follow-up extends to delivery and beyond, the prevalence of major congenital malformations and small for gestational age in their infants will be descriptively reported. Prevalence estimates will be reported separately for infants whose mothers received the COMIRNATY 2023-2024 Formula when pregnant and infants whose mothers do not have a recorded vaccination of COMIRNATY 2023-2024. Due to the relatively short length of follow-up, comparative analyses relating to pregnancy and infant outcomes will not be performed.

All results from Phase 2 analyses will be presented in the Final Report.

# 9.8. Quality Control

For the final reporting, this study will use ORD data derived from claims submitted for payment. Although the health insurance claims data represent financial transactions and are not research records, the financial transactions related to the services provided create financial incentives to record them correctly and fully, so the billable medical services represented in the database are likely to be complete. The validity of this claims research database for epidemiologic research (as compared with data abstracted from medical records)

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 30 of 148 has been widely published (Dore et al., 2011; Eng et al., 2012; Laughlin, 2011; Quam et al., 1993).

The study will be carried out according to Optum Epidemiology's internal standard operating procedures (SOPs) that are consistent with the Guidelines for Good Pharmacoepidemiology Practices (GPP) published by the European Medicines Agency (EMA) and International Society for Pharmacoepidemiology (European Medicines Agency, 2017; Public Policy Committee, International Society of Pharmacoepidemiology, 2016) as well as the FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data (FDA, 2013).

Programming for this project will be conducted by a primary analyst and reviewed by a separate analyst (validation analyst). Validation of all statistical programs and results consists of a combination of visual checks (i.e., examination of the programming log, visual printouts before and after data management steps, etc.) and computational checks (i.e., repeating calculations for comparison purposes) performed by a validation analyst. In addition, an epidemiologist and a senior scientist will perform a substantive review of all study deliverables. All validation and quality control procedures are conducted in accordance with Optum SOPs, which prescribe that processes and deliverables are documented, reviewed, and validated in sufficient detail to allow for subsequent re-examination or replication.

## 9.9. Limitations of the Research Methods

The proposed project is based on analysis of automated medical and prescription claims, including pre-adjudicated (interim reporting) and fully adjudicated claims (final reporting).

For the interim report, the SCRI analysis will be based on automated and prospectively collected pre-adjudicated medical and adjudicated prescription claims. A strength of pre-adjudicated medical claims is the shorter lag time between the receipt of care and the appearance of the claim, while the accompanying limitation is that these pre-adjudicated claims may be subject to revision during the adjudication process. A limitation of the SCRI design may be its limited ability to assess chronic outcomes such as MS. Thus, the cohort analysis will be used as the primary analysis for chronic outcomes.

While adjudicated claims data are extremely valuable for the efficient and effective examination of healthcare outcomes, treatment patterns, healthcare resource utilization, and costs, all claims databases have certain inherent limitations because the claims are collected for the purpose of payment, not research. The presence of a diagnosis code on a medical claim is not confirmation of disease, as the diagnosis code may be incorrectly coded or included as rule-out criteria rather than actual disease.

Another limitation of claims data relates to potential misclassification of exposure covariates. For instance, vaccines that are administered as part of a government program or an officebased or school-based vaccination clinic may not be captured in our database if insurance information was not provided during the vaccine encounter. This potential exposure misclassification is minimized in the self-controlled design in Phase 1; misclassification of

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 31 of 148 exposure in Phase 2 would be expected to bias the results towards the null (CDC, 2023e). Furthermore, the presence of a claim for a filled prescription does not indicate that the medication was consumed or that it was taken as prescribed. Medications paid for out-of-pocket, as well as those not dispensed through a pharmacy, will not be observed in the claims data. Similarly, we may not have complete history of comorbidity or treatment for individuals due to switching in health plan insurer.

The study power may be limited by the short duration of accrual and a limited follow-up period, particularly during Phase 1. Because the COMIRNATY 2023-2024 Formula was approved in September 2023, the study may be underpowered to conduct comparisons at the interim report stage.

Lastly, in all observational studies, treatment is not randomly assigned, and there is potential for residual confounding by factors not captured or poorly measured in claims databases. However, a strength of the current study is its incorporation of a self-controlled design, which eliminates the concern of confounding by time-fixed characteristics that vary across individuals. Similarly, in Phase 2, careful PS matching of the COMIRNATY and comparator cohorts is expected to minimize residual confounding in the cohort analysis. Finally, capture of current COVID-19 vaccines is likely better within the commercially insured population as compared to prior years, when there were more opportunities for individuals to receive a COVID-19 for free without utilizing their insurance (CDC, 2023e).

# 9.10. Other Aspects

Not applicable.

# **10. PROTECTION OF HUMAN PARTICIPANTS**

# **10.1. Patient Information**

This study involves data that exist in deidentified/anonymized structured format and contain no patient personal information.

# 10.2. Patient Consent

As this study involves deidentified/anonymized structured data, which according to applicable legal requirements do not contain data subject to privacy laws, obtaining informed consent from patients by Pfizer is not required.

# 10.3. Institutional Review Board (IRB)/Ethics Committee (EC)

Optum will prepare and submit the appropriate documents to a central IRB for Optum's conduct of the project. Optum will communicate directly with the IRB to address any questions and/or provide any additional information in connection with the review. Pfizer shall provide any necessary assistance or documents required for the submission to the IRB. Approval from an IRB for this project is not guaranteed. This project will be undertaken only after the study combined protocol/SAP has been approved by the IRB or granted an Exemption Determination Letter from the IRB. The IRB will monitor the study for the life of

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 32 of 148 the project and may require formal re-review and approval on an annual basis. Changes to the project may also require re-review and approval by the IRB.

There must be prospective approval of the study protocol/SAP, protocol/SAP amendments, and other relevant documents (e.g., informed consent forms if applicable) from the relevant IRBs or ECs. All correspondence with the IRB/EC must be retained. Copies of IRB/EC approvals must be forwarded to Pfizer.

# 10.4. Ethical Conduct of the Study

The study will be conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor and follow generally accepted research practices described in the following guidance documents:

- Guidelines for GPP. Public Policy Committee, International Society of Pharmacoepidemiology. Pharmacoepidemiology and Drug Safety 2015; 25:2-10;
- International Ethical Guidelines for Epidemiological Studies issued by the Council for International Organizations of Medical Sciences (CIOMS);
- EMA European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology;
- FDA Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment; and
- FDA Guidance for Industry and FDA Staff: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data.

# 11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS

This study involves data that exist as structured data by the time of study start. In these data sources, it is not possible to link (i.e., identify a potential association between) a particular product and medical event for any individual. Thus, the minimum criteria for reporting an adverse event (AE) (i.e., identifiable patient, identifiable reporter, a suspect product, and event) cannot be met.

# 12. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS

In the event of any prohibition or restriction imposed (e.g., clinical hold) by an applicable competent authority in any area of the world, or if Optum becomes aware of any new information which might influence the evaluation of the benefits and risks of a Pfizer product, Pfizer should be informed immediately.

#### **13. REFERENCES**

Akpandak, I., Miller, D. C., Sun, Y., Arnold, B. F., Kelly, J. D., & Acharya, N. R. (2022). Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine. JAMA Network Open, 5(11), e2242240.

https://doi.org/10.1001/jamanetworkopen.2022.42240

- Austin, P. C. (2009). Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Statistics in Medicine*, 28(25), 3083–3107. https://doi.org/10.1002/sim.3697
- Baker, M. A., Lieu, T. A., Li, L., Hua, W., Qiang, Y., Kawai, A. T., Fireman, B. H., Martin, D. B., & Nguyen, M. D. (2015). A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. *American Journal of Epidemiology*, 181(8), 608–618. https://doi.org/10.1093/aje/kwu322
- Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., Reis, B. Y., & Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *The New England Journal of Medicine*, 385(12), 1078–1090. https://doi.org/10.1056/NEJMoa2110475
- Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J., & Stürmer, T. (2006). Variable selection for propensity score models. *American Journal of Epidemiology*, 163(12), 1149–1156. https://doi.org/10.1093/aje/kwj149

CBER. (2022). Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and

Safety (BEST) Initiative: Safety Assessment of 3<sup>rd</sup> Dose/Booster of COVID-19 mRNA Vaccines: Master Protocol. U.S. Food and Drug Administration. https://bestinitiative.org/wp-content/uploads/2022/09/C19-Post-Booster-Dose-AESI-

- Risk-Protocol-2022.pdf
- CBER. (2021). Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) System COVID-19 Vaccine Safety Surveillance: Active Monitoring Master Protocol. U.S. Food and Drug Administration. https://bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-Protocol-2021.pdf
- CDC. (2023a). *Metropolitan Atlanta Congenital Defects Program (MACDP)*. Centers for Disease Control and Prevention.

https://www.cdc.gov/ncbddd/birthdefects/macdp.html

CDC. (2023b). Immunization Information Systems COVID-19 Vaccine-Related Codes: Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently Authorized Vaccines and Anticipation of Potential Vaccine Availability under

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 34 of 148 Emergency Use Authorization (EUA).

https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html

- CDC. (2023c). Immunization Information Systems (IIS) Code Sets. https://www.cdc.gov/vaccines/programs/iis/code-sets.html
- CDC. (2023d). Weekly COVID-19 vaccination dashboard. https://cdc.gov/vaccines/imzmanagers/coverage/covidvaxview/interactive/vaccination-dashboard.html.

CDC. (2023e). HHS Launches Bridge Access Program to Safeguard Free COVID-19

Vaccination

for Uninsured and Underinsured Adults.

https://www.cdc.gov/media/releases/2023/p0914-uninsured-vaccination.html

- CDC. (2020). *COVID Data Tracker*. US Department of Health and Human Services, CDC. https://covid.cdc.gov/covid-data-tracker
- Chomistek, A. K., Phiri, K., Doherty, M. C., Calderbank, J. F., Chiuve, S. E., McIlroy, B. H., Snabes, M. C., Enger, C., & Seeger, J. D. (2023). Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes. *Drug Safety*, 46(2), 209–222. https://doi.org/10.1007/s40264-022-01261-5
- Dore, D. D., Bloomgren, G. L., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D. (2011). A cohort study of acute pancreatitis in relation to exenatide use. *Diabetes, Obesity & Metabolism, 13*(6), 559–566. https://doi.org/10.1111/j.1463-1326.2011.01376.x
- Dore, D. D., Turnbull, B. R., & Seeger, J. D. (2012). Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. *Pharmacoepidemiology and Drug Safety*, 21(4), 415–419. https://doi.org/10.1002/pds.3217
- Eng, P. M., Mast, T. C., Loughlin, J., Clifford, C. R., Wong, J., & Seeger, J. D. (2012).
  Incidence of intussusception among infants in a large commercially insured population in the United States. *The Pediatric Infectious Disease Journal*, 31(3), 287– 291. https://doi.org/10.1097/INF.0b013e31824213b1
- EUROCAT. (2020). EUROCAT Subgroups of Congenital Anomalies (Version 2014; implemented in EDMP December 2014, used for website prevalence tables from December 2014). European Network of Population-Based Registries for the Epidemiological Surveillance of Congenital Anomalies, European Platform on Rare Disease Registration, European Commission. https://eu-rdplatform.jrc.ec.europa.eu/sites/default/files/JRC-EUROCAT-Section-3.3-23-9-2020.pdf

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 35 of 148

- European Medicines Agency. (2017). Guideline on good pharmacovigilance practices (GVP)—Module VI Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2).
- FDA. (2013). Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data. U.S. Department of Health and Human Services. https://www.fda.gov/media/79922/download
- FDA. (2023a). Janssen COVID-19 Vaccine. *FDA*. https://www.fda.gov/vaccines-bloodbiologics/coronavirus-covid-19-cber-regulated-biologics/janssen-covid-19-vaccine
- FDA. (2020a). FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. FDA; FDA. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fightagainst-covid-19-issuing-emergency-use-authorization-first-covid-19
- FDA. (2020b). FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. FDA; FDA. https://www.fda.gov/news-events/press-announcements/fda-takes-additional-actionfight-against-covid-19-issuing-emergency-use-authorization-second-covid
- FDA. (2021a). FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. FDA; FDA. https://www.fda.gov/news-events/press-announcements/fda-issuesemergency-use-authorization-third-covid-19-vaccine
- FDA. (2021b). Vaccines and Related Biological Products Advisory Committee June 10, 2021 Meeting Presentation: FDA Updates of COVID-19 Vaccine Safety Activities. https://www.fda.gov/media/150051/download
- FDA. (2022a). Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted. FDA; FDA. https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergencyuse-novavax-covid-19-vaccine-adjuvanted
- FDA. (2022b). Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. FDA; FDA. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use
- FDA. (2022c). Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups. FDA; FDA. https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizerbiontech-bivalent-covid-19-vaccines

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 36 of 148
- FDA. (2022d). Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age. FDA; FDA. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19update-fda-authorizes-updated-bivalent-covid-19-vaccines-children-down-6-months
- FDA. (2023b). FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. FDA; FDA. https://www.fda.gov/newsevents/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccinesbetter-protect-against-currently-circulating
- Guertin, J. R., Rahme, E., & LeLorier, J. (2016). Performance of the high-dimensional propensity score in adjusting for unmeasured confounders. *European Journal of Clinical Pharmacology*, 72(12), 1497–1505. https://doi.org/10.1007/s00228-016-2118-x
- Janssen Pharmaceutical Companies. (2023). Janssen COVID-19 Vaccine: Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers). https://www.fda.gov/media/146304/download?attachment
- Joy, M., Agrawal, U., Fan, X., Robertson, C., Anand, S. N., Ordonez-Mena, J., Byford, R., Goudie, R., Jamie, G., Kar, D., Williams, J., Marsden, G. L., Tzortziou-Brown, V., Sheikh, S. A., Hobbs, F. D. R., & de Lusignan, S. (2023). Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: Self-controlled case series analysis of the English national sentinel cohort. *The Lancet Regional Health - Europe*, *32*, 100681. https://doi.org/10.1016/j.lanepe.2023.100681
- Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., Donahue, J. G., Kharbanda, E. O., Naleway, A., Nelson, J. C., Xu, S., Yih, W. K., Glanz, J. M., Williams, J. T. B., Hambidge, S. J., Lewin, B. J., Shimabukuro, T. T., DeStefano, F., & Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. *JAMA*, 326(14), 1–10. https://doi.org/10.1001/jama.2021.15072
- Laughlin, L. L. (2011). Maternity leave and employment patterns of first-time mothers: 1961-2008. U.S. Dept. of Commerce, Economics and Statistics Administration, U.S. Census Bureau.
- Law, B., & Sturkenboom, M. (2020). Priority list of adverse events of special interest: COVID-19. 2020. Safety Platform for Emergency Vaccines (SPEAC). https://brightoncollaboration.us/wpcontent/uploads/2020/06/SPEAC D2.3 V2.0 COVID-19 20200525 public.pdf

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 37 of 148

Liu, J., Cao, F., Luo, C., Guo, Y., & Yan, J. (2023). Stroke Following COVID-19 Vaccination: Evidence Based on Different Designs of Real-World Studies. *The Journal of Infectious Diseases*, jiad306. https://doi.org/10.1093/infdis/jiad306

Martin, T. J., Fahey, M., Easton, M., Clothier, H. J., Samuel, R., Crawford, N. W., & Buttery, J. P. (2021). Acute disseminated encephalomyelitis and routine childhood vaccinations—A self-controlled case series. *Human Vaccines & Immunotherapeutics*, 17(8), 2578–2585. https://doi.org/10.1080/21645515.2021.1901544

McCarthy, N. L., Gee, J., Lin, N. D., Thyagarajan, V., Pan, Y., Su, S., Turnbull, B., Chan, K. A., & Weintraub, E. (2013). Evaluating the safety of influenza vaccine using a claims-based health system. *Vaccine*, *31*(50), 5975–5982. https://doi.org/10.1016/j.vaccine.2013.10.031

Moderna US, Inc. (2023). SPIKEVAX Prescribing Information. https://www.fda.gov/media/155675/download?attachment

Moll, K., Lufkin, B., Fingar K., Zhou, C. K., Tworkoski, E., Shi, C., Hobbix, S., Hu, M., Sheng, M.,

McCarty, J., Shangguan, S., Burrell, T., Chillarige, Y., Beers, J., Sauders-Hastings,

Р.,

Edwards, K., Muthuri, S., Black, S., Kelman, J., Reich, C., Amend, K. L., Beachler, D.,

Ogilvie, R. P., Secora, A., Mcmahill-Walracenm C. N., Seeger, J. D., Lloyd, P., Thompson,

D., Dimova, R., MaCurdy, T., Obidi, J., Anderson, S. A., Forshee, R., Wong, HL., Shoaibim

A. (2023). Events of special interest for COVID-19 vaccine safety monitoring in the United

States, 2019-2020. Vaccine, 41(2), 333-353.

Myers, J. A., Rassen, J. A., Gagne, J. J., Huybrechts, K. F., Schneeweiss, S., Rothman, K. J., Joffe, M. M., & Glynn, R. J. (2011). Effects of adjusting for instrumental variables on bias and precision of effect estimates. *American Journal of Epidemiology*, 174(11), 1213–1222. https://doi.org/10.1093/aje/kwr364

Nabizadeh, F., Noori, M., Rahmani, S., & Hosseini, H. (2023). Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review. *Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia*, 111, 57–70. https://doi.org/10.1016/j.jocn.2023.03.008

New York State Department of Health Birth Defects Registry. (2021). New York State Department of Health Congenital Malformations Registry ICD-10 Coding Manual:

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 38 of 148 List of all Reportable Congenital Malformations.

https://www.health.ny.gov/diseases/birth\_defects/docs/icd.pdf

- Normand, S. T., Landrum, M. B., Guadagnoli, E., Ayanian, J. Z., Ryan, T. J., Cleary, P. D., & McNeil, B. J. (2001). Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores. *Journal of Clinical Epidemiology*, 54(4), 387–398. https://doi.org/10.1016/s0895-4356(00)00321-8
- Parsons, L. S. (2001). Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. *Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference*.
- Pfizer Inc/BioNTech. (2023). COMIRNATY Prescribing Information. https://www.fda.gov/media/151707/download?attachment
- Public Policy Committee, International Society of Pharmacoepidemiology. (2016). Guidelines for good pharmacoepidemiology practice (GPP). *Pharmacoepidemiology and Drug Safety*, 25(1), 2–10. https://doi.org/10.1002/pds.3891
- Quam, L., Ellis, L. B., Venus, P., Clouse, J., Taylor, C. G., & Leatherman, S. (1993). Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. *Medical Care*, 31(6), 498–507.

Schneider, K. L., Bell, E. J., Zhou, C. K., Yang, G., Lloyd, P., Clarke, T. C., Wilkinson, M., Myers,

E. E., Amend, K. L., Seeger, J. D., Chillarige, Y., Forshee, R., Shoaibi, A., Anderson, S. A.,

Wong, HL. Immunization information systems to improve assertainment of COVID-19 vaccinations for claimes-based vaccine safety and effectiveness studies. (2023). *JAMA Network Open*,6(5), e2313512.

Seeger, J. D., Amend, K. L., Turnbull, B. R., Zhou, L., Marks, M. A., Velicer, C., & Saddier, P. (2023). Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States. *Vaccine*, 41(11), 1826–1833. https://doi.org/10.1016/j.vaccine.2022.10.050

Vaccine Adverse Event Reporting System (VAERS). (2023). [CDC WONDER On-line Database.]. United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC), Food and Drug Administration (FDA). http://wonder.cdc.gov/vaers.html

Wack, S., Patton, T., & Ferris, L. K. (2021). COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence.

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 39 of 148 Journal of the American Academy of Dermatology, 85(5), 1274–1284. https://doi.org/10.1016/j.jaad.2021.07.054

- Xu, S., Hong, V., Sy, L. S., Glenn, S. C., Ryan, D. S., Morrissette, K. L., Nelson, J. C., Hambidge, S. J., Crane, B., Zerbo, O., DeSilva, M. B., Glanz, J. M., Donahue, J. G., Liles, E., Duffy, J., & Qian, L. (2022). Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic. *Vaccine*, 40(23), 3150–3158. https://doi.org/10.1016/j.vaccine.2022.04.037
- Ziyadeh, N. J., Geldhof, A., Noël, W., Otero-Lobato, M., Esslinger, S., Chakravarty, S. D., Wang, Y., & Seeger, J. D. (2020). Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database. *Clinical Drug Investigation*, 40(11), 1021–1040. https://doi.org/10.1007/s40261-020-00959-7

# **14. LIST OF TABLES**

Table 1.	Study design and data sources for interim and final reporting16
Table 2.	Clean periods and risk intervals for safety outcomes of interest23
15. LIST OF FIGURES	
Figure 1.	Self-controlled risk interval design

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 41 of 148

## ANNEX 1. LIST OF STANDALONE DOCUMENTS

None.

# ANNEX 2. CODE LISTS

CPT copyright 2022 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

## 1. APPENDIX I – COMIRNATY 2023-2024 FORMULA

The following CPT and NDC codes are sourced from the Immunization Information Systems (IIS) at the Center for Disease Control and Prevention (CDC, 2023b). Other codes will be included as they become available.

## 15.1.1. CPT Codes

91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

# 15.1.2. NDC Codes

00069-2362-01 Ages 12 years and older; VIAL, SINGLE-DOSE, 30 mcg/0.3 mL

00069-2392-01 Ages 12 years and older; SYRINGE, PRE-FILLED, 30 mcg/0.3 mL

59267-4331-01 Ages 5 through 11 years; VIAL, SINGLE-DOSE, 10 mcg/0.3 mL

59267-4315-01 Ages 6 months through 4 years; VIAL, MULTI-DOSE, 3 DOSES, 3mcg / 0.3 mL AFTER DILUTION

#### **15.2.** Appendix II – Comparator Codes

# **15.2.1. COVID-19 Vaccine 2023-2024 Formulations Other than the COMIRNATY 2023-2024 Formula**

#### 15.2.1.1. Moderna Spikevax

## 15.2.1.1.1. CPT Codes<sup>3</sup>

91322 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use

91321 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use

## 15.2.1.1.2. NDC Codes

80777-0102-04 -- Ages 12 years and older; VIAL, SINGLE-DOSE, 50 mcg/0.5 mL

80777-0102-01 -- Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 mL

80777-0287-07 -- v25 mL

# 15.2.1.2. Novavax COVID-19 Vaccine, Adjuvanted

## 15.2.1.2.1. CPT codes

91304 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use

0041A -- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL

0042A -- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 44 of 148

<sup>&</sup>lt;sup>3</sup> CPT copyright 2022 American Medical Association. All rights reserved.

0044A -- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL

# 15.2.1.2.2. NDC Codes

80631-0105-01 -- Ages 12 years and older; VIAL, MULTI-DOSE, 5 DOSES, 5 mcg/0.5 mL

## 15.2.2. Other Vaccines

CPT and NDC codes are sourced from the Immunization Information Systems (IIS) at the Center for Disease Control and Prevention (CDC, 2023c). Other codes will be included as they become available.

## 15.2.2.1. CPT Codes<sup>4</sup>

90630, 90653-90664, 90666-90668, 90672-90674, 90682-90689, 90694, 90724, 90756	Influenza virus vaccine
90380-90381, 90678-90679, 96380- 96381	Respiratory syncytial virus vaccine
90470	H1N1 immunization
90476-90477	Adenovirus vaccine
90581	Anthrax vaccine
90585, 90728	Tuberculosis BGC vaccine
90611, 90622	Smallpox/monkeypox vaccine
90619-90621, 90644, 90733-90734	Meningococcal vaccine
90625, 90725	Cholera vaccine
90626-90627, 90738	Tick-borne/Japanese encephalitis virus vaccine
90632-90636, 90730	Hepatitis A vaccine

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 45 of 148

<sup>&</sup>lt;sup>4</sup> CPT copyright 2022 American Medical Association. All rights reserved.

90636, 90739-90740, 90743-90748, 90759, 90731	Hepatitis B vaccine
90645-90648, 90737	Hemophilus influenza type B vaccine
90649-90651	Human Papillomavirus vaccine
90665	Lyme disease vaccine
90669-90671, 90732 <sup>5</sup>	Pneumococcal vaccine
90675-90676, 90726	Rabies vaccine
90680-90681	Rotavirus vaccine
90690-90693	Typhoid vaccine
90696-90702, 90714-90715, 90720- 90723	Diphtheria vaccine
90696-90703, 90714-90715, 90723	Tetanus vaccine
90696-90698, 90700, 90715, 90723	Pertussis vaccine
90704, 90707, 90709-90710	Mumps vaccine
90705, 90707-90708, 90710	Measles vaccine
90706, 90707-90710	Rubella vaccine
90696-90698, 90712-90713	Poliovirus vaccine
90710, 90716	Varicella virus vaccine
90717	Yellow fever vaccine
90727	Plague vaccine
90736, 90750	Zoster (shingles) vaccine
90758	Ebolavirus vaccine
90584, 90587	Dengue vaccine

<sup>&</sup>lt;sup>5</sup> CPT copyright 2022 American Medical Association. All rights reserved.

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 46 of 148

## 15.2.2.2. NDC Codes

The below list includes generic vaccine names classified by therapeutic use. Codes for generic vaccines are based on the Hierarchical Ingredient Code List (HICL) system proprietary to First Databank. All associated NDC codes will be utilized. Other vaccines will be included as they become available.

Adenovirus vaccine, live Anthrax vaccine Anthrax vaccine, adsorbed BCG vaccine BCG vaccine, live Cholera vaccine Dengue vaccine Diphtheria, pertussis, tetanus, and haemophilis influenzae type B vaccine Hepatitis A virus vaccine Hepatitis A virus and hepatitis B virus vaccine Hepatitis B and haemophilus influenzae type B vaccine Hepatitis B, diphtheria, and poliomyelitis virus vaccine Hepatitis B, haemophilus influenzae type B, and meningococcal vaccine Hepatitis B virus vaccine HPV vaccine Influenza A (H1N1) vaccine Influenza A (H1N1) vaccine, live Influenza virus vaccine Influenza virus vaccine, trivalent Influenza virus vaccine, trivalent, live Japanese encephalitis vaccine

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 47 of 148

Measles and rubella vaccine Measles, mumps, and rubella vaccine Measles vaccine, live, attenuated Mumps vaccine, live Plague vaccine Poliomyelitis vaccine, killed Poliomyelitis vaccine, live Rabies vaccine Rabies vaccine, human diploid Rotavirus vaccine, live Rubella and mumps vaccine Rubella vaccine Smallpox, monkeypox, live Smallpox vaccine, live Staphylococcus vaccine Typhoid vaccine Varicella virus vaccine, live Yellow fever vaccine Zoster vaccine, live 15.2.3. Outpatient Codes **CPT Codes**<sup>6</sup>

99201-99205 99211-99215 99241-99245 99354-99355

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 48 of 148

<sup>&</sup>lt;sup>6</sup> CPT copyright 2022 American Medical Association. All rights reserved.

## 99381-99387 99391-99397

# 15.3. Appendix III – Safety Outcomes of Interest

All codes are ICD-10 diagnosis codes; all outcomes will be defined based on the presence of a single code unless otherwise specified. In order to qualify as an outcome, the outcomespecific codes must be identified during emergency department visits, inpatient hospitalizations, or outpatient visits, as detailed in Table 2. Outpatient visits are defined through physician evaluation and management codes (Section 17.2.3).

\* Outcome codes marked with an asterisk are based on COVID-19 vaccine studies conducted as part of the FDA's CBER BEST system.

- Acute disseminated encephalomyelitis (ADEM)\*
  - o G04.00 Acute disseminated encephalitis and encephalomyelitis, unspecified
- Anaphylaxis\*
  - o T80.52XA Anaphylactic reaction due to vaccination, initial encounter
  - o T78.2XXA Anaphylactic shock, unspecified, initial encounter
- Bell's palsy\*
  - G51.0 Bell's palsy
  - G51.8 Other disorders of facial nerve
  - o G51.9 Disorder of facial nerve, unspecified
- Cerebral venous sinus thrombosis (CVST)
  - I67.6 Nonpyogenic thrombosis of intracranial venous system
  - $\circ$  I63.6 Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
- Convulsions/seizures (non-febrile)
  - G40.001 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status epilepticus
  - G40.009 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus
  - G40.011 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus
  - G40.019 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus

## PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 49 of 148

- G40.101 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus
- G40.109 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus
- G40.111 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus
- G40.119 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus
- G40.201 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus
- G40.209 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus
- G40.211 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
- G40.219 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus
- G40.301 Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus
- G40.309 Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus
- G40.311 Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus
- G40.319 Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus
- G40.401 Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus
- G40.409 Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus
- G40.411 Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 50 of 148

- G40.419 Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus
- G40.501 Epileptic seizures related to external causes, not intractable, with status epilepticus
- G40.509 Epileptic seizures related to external causes, not intractable, without status epilepticus
- G40.801 Other epilepsy, not intractable, with status epilepticus
- o G40.802 Other epilepsy, not intractable, without status epilepticus
- o G40.803 Other epilepsy, intractable, with status epilepticus
- o G40.804 Other epilepsy, intractable, without status epilepticus
- o G40.811 Lennox-Gastaut syndrome, not intractable, with status epilepticus
- G40.812 Lennox-Gastaut syndrome, not intractable, without status epilepticus
- o G40.813 Lennox-Gastaut syndrome, intractable, with status epilepticus
- o G40.814 Lennox-Gastaut syndrome, intractable, without status epilepticus
- o G40.821 Epileptic spasms, not intractable, with status epilepticus
- o G40.822 Epileptic spasms, not intractable, without status epilepticus
- o G40.823 Epileptic spasms, intractable, with status epilepticus
- o G40.824 Epileptic spasms, intractable, without status epilepticus
- G40.89 Other seizures
- G40.901 Epilepsy, unspecified, not intractable, with status epilepticus
- o G40.909 Epilepsy, unspecified, not intractable, without status epilepticus
- o G40.911 Epilepsy, unspecified, intractable, with status epilepticus
- o G40.919 Epilepsy, unspecified, intractable, without status epilepticus
- G40.A01 Absence epileptic syndrome, not intractable, with status epilepticus
- G40.A09 Absence epileptic syndrome, not intractable, without status epilepticus
- o G40.A11 Absence epileptic syndrome, intractable, with status epilepticus
- o G40.A19 Absence epileptic syndrome, intractable, without status epilepticus
- G40.B01 Juvenile myoclonic epilepsy, not intractable, with status epilepticus
- G40.B09 Juvenile myoclonic epilepsy, not intractable, without status epilepticus

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 51 of 148

- G40.B11 Juvenile myoclonic epilepsy, intractable, with status epilepticus
- o G40.B19 Juvenile myoclonic epilepsy, intractable, without status epilepticus
- R56.1 Post traumatic seizures
- R56.9 Unspecified convulsions
- Encephalomyelitis\*
  - G04.02 Postimmunization acute disseminated encephalitis, myelitis, and encephalomyelitis
  - o G04.00 Acute disseminated encephalitis and encephalomyelitis, unspecified
  - o G04.81 Other encephalitis and encephalomyelitis
  - o G04.90 Encephalitis and encephalomyelitis
  - o G05.3 Encephalitis and encephalomyelitis in diseases classified elsewhere
- Glomerulonephritis
  - o N06.A Isolated proteinuria with C3 glomerulonephritis
  - o N06.7 Isolated proteinuria with diffuse crescentic glomerulonephritis
  - o N06.5 Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis
  - N06.4 Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis
  - N04.A Nephrotic syndrome with C3 glomerulonephritis
  - o N04.2 Nephrotic syndrome with diffuse membranous glomerulonephritis
  - N04.7 Nephrotic syndrome with diffuse crescentic glomerulonephritis
  - o N04.5 Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis
  - N04.3 Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis
  - N04.4 Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis
  - $\circ$   $\,$  N05.A Unspecified nephritic syndrome with C3 glomerulonephritis
  - N05.7 Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis
  - N05.2 Unspecified nephritic syndrome with diffuse membranous glomerulonephritis
  - N05.5 Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
  - o N03.A Chronic nephritic syndrome with C3 glomerulonephritis

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 52 of 148

- N03.7 Chronic nephritic syndrome with diffuse crescentic glomerulonephritis
- N03.2 Chronic nephritic syndrome with diffuse membranous glomerulonephritis
- N03.5 Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
- N00.A Acute nephritic syndrome with C3 glomerulonephritis
- o N00.2 Acute nephritic syndrome with diffuse membranous glomerulonephritis
- N00.5 Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
- o N00.7 Acute nephritic syndrome with diffuse crescentic glomerulonephritis
- N07.A Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis
- N02.7 Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis
- N02.A Recurrent and persistent hematuria with C3 glomerulonephritis
- Guillain-Barré syndrome\*
  - G61.0 Guillain-Barré syndrome
- Herpes zoster
  - B02.\* Zoster [herpes zoster]
- Immune-mediated myositis
  - G72.41 Inclusion body myositis [IBM]
  - o M33 Dermatopolymyositis
  - o M33.0 Juvenile dermatomyositis
  - o M33.00 Juvenile dermatomyositis, organ involvement unspecified
  - $\circ$  M33.01 Juvenile dermatomyositis with respiratory involvement
  - o M33.02 Juvenile dermatomyositis with myopathy
  - o M33.03 Juvenile dermatomyositis without myopathy
  - $\circ$  M33.09 Juvenile dermatomyositis with other organ involvement
  - o M33.1 Other dermatomyositis
  - $\circ$  M33.10 Other dermatomyositis, organ involvement unspecified
  - $\circ$  M33.11 Other dermatomyositis with respiratory involvement
  - o M33.12 Other dermatomyositis with myopathy
  - o M33.13 Other dermatomyositis without myopathy

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023

- M33.19 Other dermatomyositis with other organ involvement
- M33.2 Polymyositis
- o M33.20 Polymyositis, organ involvement unspecified
- o M33.21 Polymyositis with respiratory involvement
- o M33.22 Polymyositis with myopathy
- o M33.29 Polymyositis with other organ involvement
- o M33.9 Dermatopolymyositis, unspecified
- o M33.90 Dermatopolymyositis, unspecified, organ involvement unspecified
- o M33.91 Dermatopolymyositis, unspecified with respiratory involvement
- o M33.92 Dermatopolymyositis, unspecified myopathy
- o M33.93 Dermatopolymyositis, unspecified without myopathy
- o M33.99 Dermatopolymyositis, unspecified with other organ involvement
- o G72.41 Other and unspecified myopathies
- $\circ$  G72.0 Drug-induced myopathy
- $\circ$  G72.2 Myopathy due to other toxic agents
- o G72.41 Inflammatory and immune myopathies, not elsewhere
- $\circ$  G72.49 Other inflammatory and immune myopathies, not elsewhere classified
- o G72.8 Other specified myopathies
- o G72.9 Myopathy, unspecified
- o G73.7 Myopathy in diseases classified elsewhere
- o M36.0 Dermato(poly)myositis in neoplastic disease
- o I42.7 Cardiomyopathy due to drug and external agent
- $\circ$  I42.9 Cardiomyopathy, unspecified
- $\circ$  I43 Cardiomyopathy in diseases classified elsewhere
- $\circ$  I42 Cardiomyopathy
- o M79.1 Myalgia
- M79.7 Fibromyalgia
- o I42.5 Other restrictive cardiomyopathy
- I42.8 Other cardiomyopathies
- Immune thrombocytopenia\*

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 54 of 148

- D69.3 Immune thrombocytopenic purpura
- Kawasaki disease\*
  - o M30.3 Mucocutaneous lymph node syndrome [Kawasaki]
- Multi inflammatory syndrome (in children and adults)\*
  - U07.1 COVID-19 and one of the following:
  - M35.8 Other specified systemic involvement of connective tissue
  - o M35.81 Multisystem inflammatory syndrome
  - o M35.89 Other specified systemic involvement of connective tissue
- Multiple sclerosis
  - G35 Multiple sclerosis
- Myocardial infarction\*
  - I21.01 ST elevation (STEMI) myocardial infarction involving left main coronary artery
  - I21.02 ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
  - I21.09 ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
  - $\circ~$  I21.11 ST elevation (STEMI) myocardial infarction involving right coronary artery
  - I21.19 ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
  - I21.21 ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
  - o I21.29 ST elevation (STEMI) myocardial infarction involving other sites
  - o I21.3 ST elevation (STEMI) myocardial infarction of unspecified site
  - o I21.4 Non-ST elevation (NSTEMI) myocardial infarction
  - o I21.9 Acute myocardial infarction, unspecified
  - I21.A1 Myocardial infarction type 2
  - o I21.A9 Other myocardial infarction type
  - I22.0 Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
  - I22.1 Subsequent ST elevation (STEMI) myocardial infarction of inferior wall

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 55 of 148

- o I22.2 Subsequent non-ST elevation (NSTEMI) myocardial infarction
- o I22.8 Subsequent ST elevation (STEMI) myocardial infarction of other sites
- I22.9 Subsequent ST elevation (STEMI) myocardial infarction of unspecified site
- Myocarditis/pericarditis\*
  - B33.22 Viral myocarditis
  - o B33.23 Viral pericarditis
  - I30.0 Acute nonspecific idiopathic pericarditis
  - I30.1 Infective pericarditis
  - I30.8 Other forms of acute pericarditis
  - o I30.9 Acute pericarditis, unspecified
  - o I32 Pericarditis in diseases classified elsewhere
  - o I41 Myocarditis in diseases classified elsewhere
  - I40.0 Infective myocarditis
  - I40.1 Isolated myocarditis
  - I40.8 Other acute myocarditis
  - I40.9 Acute myocarditis, unspecified
  - I51.4 Myocarditis, unspecified
- Pulmonary embolism\*
  - I26.02 Saddle embolus of pulmonary artery with acute cor pulmonale
  - o I26.09 Other pulmonary embolism with acute cor pulmonale
  - o I26.92 Saddle embolus of pulmonary artery without acute cor pulmonale
  - I26.93 Single subsegmental pulmonary embolism without acute cor pulmonale
  - I26.94 Multiple subsegmental pulmonary emboli without acute cor pulmonale
  - $\circ$  I26.99 Other pulmonary embolism without acute cor pulmonale
- Stroke, hemorrhagic\*
  - $\circ$  I61.0 Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
  - o I61.1 Nontraumatic intracerebral hemorrhage in hemisphere, cortical
  - o I61.2 Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
  - I61.3 Nontraumatic intracerebral hemorrhage in brain stem

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 56 of 148

- o I61.4 Nontraumatic intracerebral hemorrhage in cerebellum
- o I61.5 Nontraumatic intracerebral hemorrhage, intraventricular
- o I61.6 Nontraumatic intracerebral hemorrhage, multiple localized
- o I61.8 Other nontraumatic intracerebral hemorrhage
- o I61.9 Nontraumatic intracerebral hemorrhage, unspecified
- o I62.00 Nontraumatic subdural hemorrhage, unspecified
- o I62.01 Nontraumatic acute subdural hemorrhage
- o I62.02 Nontraumatic subacute subdural hemorrhage
- o I62.9 Nontraumatic intracranial hemorrhage, unspecified
- Stroke, ischemic\*
  - I63.00 Cerebral infarction due to thrombosis of unspecified precerebral artery
  - $\circ$  I63.011 Cerebral infarction due to thrombosis of right vertebral artery
  - I63.012 Cerebral infarction due to thrombosis of left vertebral artery
  - I63.013 Cerebral infarction due to thrombosis of bilateral vertebral arteries
  - I63.019 Cerebral infarction due to thrombosis of unspecified vertebral artery
  - I63.02 Cerebral infarction due to thrombosis of basilar artery
  - o I63.031 Cerebral infarction due to thrombosis of right carotid artery
  - o I63.032 Cerebral infarction due to thrombosis of left carotid artery
  - I63.033 Cerebral infarction due to thrombosis of bilateral carotid arteries
  - o I63.039 Cerebral infarction due to thrombosis of unspecified carotid artery
  - I63.09 Cerebral infarction due to thrombosis of other precerebral artery
  - o I63.10 Cerebral infarction due to embolism of unspecified precerebral artery
  - o I63.111 Cerebral infarction due to embolism of right vertebral artery
  - $\circ$  I63.112 Cerebral infarction due to embolism of left vertebral artery
  - o I63.113 Cerebral infarction due to embolism of bilateral vertebral arteries
  - o I63.119 Cerebral infarction due to embolism of unspecified vertebral artery
  - $\circ$  I63.12 Cerebral infarction due to embolism of basilar artery
  - $\circ$  I63.131 Cerebral infarction due to embolism of right carotid artery
  - $\circ$  I63.132 Cerebral infarction due to embolism of left carotid artery
  - o I63.133 Cerebral infarction due to embolism of bilateral carotid arteries

- o I63.139 Cerebral infarction due to embolism of unspecified carotid artery
- o I63.19 Cerebral infarction due to embolism of other precerebral artery
- I63.20 Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries
- I63.211 Cerebral infarction due to unspecified occlusion or stenosis of right vertebral arteries
- I63.212 Cerebral infarction due to unspecified occlusion or stenosis of left vertebral arteries
- I63.213 Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries
- I63.219 Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries
- I63.22 Cerebral infarction due to unspecified occlusion or stenosis of basilar arteries
- I63.231 Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
- I63.232 Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries
- I63.233 Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries
- I63.239 Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries
- I63.29 Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries
- I63.30 Cerebral infarction due to thrombosis of unspecified cerebral artery
- I63.311 Cerebral infarction due to thrombosis of right middle cerebral artery
- I63.312 Cerebral infarction due to thrombosis of left middle cerebral artery
- I63.313 Cerebral infarction due to thrombosis of bilateral middle cerebral arteries
- I63.319 Cerebral infarction due to thrombosis of unspecified middle cerebral artery
- I63.321 Cerebral infarction due to thrombosis of right anterior cerebral artery
- o I63.322 Cerebral infarction due to thrombosis of left anterior cerebral artery
- I63.323 Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 58 of 148

- I63.329 Cerebral infarction due to thrombosis of unspecified anterior cerebral artery
- I63.331 Cerebral infarction due to thrombosis of right posterior cerebral artery
- I63.332 Cerebral infarction due to thrombosis of left posterior cerebral artery
- I63.333 Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries
- I63.339 Cerebral infarction due to thrombosis of unspecified posterior cerebral artery
- I63.341 Cerebral infarction due to thrombosis of right cerebellar artery
- o I63.342 Cerebral infarction due to thrombosis of left cerebellar artery
- I63.343 Cerebral infarction due to thrombosis of bilateral cerebellar artery
- I63.349 Cerebral infarction due to thrombosis of unspecified cerebellar artery
- o I63.39 Cerebral infarction due to thrombosis of other cerebral artery
- o I63.40 Cerebral infarction due to embolism of unspecified cerebral artery
- I63.411 Cerebral infarction due to embolism of right middle cerebral artery
- I63.412 Cerebral infarction due to embolism of left middle cerebral artery
- I63.413 Cerebral infarction due to embolism of bilateral middle cerebral artery
- I63.419 Cerebral infarction due to embolism of unspecified middle cerebral arteries
- o I63.421 Cerebral infarction due to embolism of right anterior cerebral artery
- I63.422 Cerebral infarction due to embolism of left anterior cerebral artery
- I63.423 Cerebral infarction due to embolism of bilateral anterior cerebral arteries
- I63.429 Cerebral infarction due to embolism of unspecified anterior cerebral artery
- I63.431 Cerebral infarction due to embolism of right posterior cerebral artery
- o I63.432 Cerebral infarction due to embolism of left posterior cerebral artery
- I63.433 Cerebral infarction due to embolism of bilateral anterior cerebral arteries

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 59 of 148

- I63.439 Cerebral infarction due to embolism of unspecified posterior cerebral artery
- o I63.441 Cerebral infarction due to embolism of right cerebellar artery
- o I63.442 Cerebral infarction due to embolism of left cerebellar artery
- I63.443 Cerebral infarction due to embolism of bilateral cerebellar arteries
- o I63.449 Cerebral infarction due to embolism of unspecified cerebellar artery
- o I63.49 Cerebral infarction due to embolism of other cerebellar artery
- o I63.50 Cerebral infarction due to embolism of unspecified cerebral artery
- I63.511 Cerebral infarction due to embolism of right middle cerebral artery
- o I63.512 Cerebral infarction due to embolism of left middle cerebral artery
- I63.513 Cerebral infarction due to embolism of bilateral middle cerebral arteries
- I63.519 Cerebral infarction due to embolism of unspecified middle cerebral artery
- o I63.521 Cerebral infarction due to embolism of right anterior cerebral artery
- o I63.522 Cerebral infarction due to embolism of left anterior cerebral artery
- I63.523 Cerebral infarction due to embolism of bilateral anterior cerebral artery
- I63.529 Cerebral infarction due to embolism of unspecified anterior cerebral artery
- I63.531 Cerebral infarction due to embolism of right posterior cerebral artery
- o I63.532 Cerebral infarction due to embolism of left posterior cerebral artery
- I63.533 Cerebral infarction due to embolism of bilateral posterior cerebral arteries
- I63.539 Cerebral infarction due to embolism of unspecified posterior cerebral artery
- o I63.541 Cerebral infarction due to embolism of right cerebellar artery
- I63.542 Cerebral infarction due to embolism of left cerebellar artery
- o I63.543 Cerebral infarction due to embolism of bilateral cerebellar arteries
- $\circ$  I63.549 Cerebral infarction due to embolism of unspecified cerebellar artery
- o I63.59 Cerebral infarction due to embolism of other cerebellar artery
- $\circ$  I63.6 Cerebral infarction dye to cerebral venous thrombosis, nonpyogenic
- o I63.81 Other cerebral infarction due to occlusion or stenosis of small artery

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 60 of 148

- o I63.89 Other cerebral infarction
- I63.9 Cerebral infarction, unspecified
- Transverse myelitis\*
  - G37.3 Acute transverse myelitis in demyelinating disease of central nervous system

In Phase 2 of the study, the following pregnancy outcomes will be assessed in pregnant women or their infants, if sample size permits:

- Spontaneous abortion (Chomistek et al., 2023)
  - OOO2.1 Missed abortion
  - O03.\*\* Spontaneous abortion
  - O03.0 Genital tract and pelvic infection following incomplete spontaneous abortion
  - O03.1 Delayed or excessive hemorrhage following incomplete spontaneous abortion
  - 0 O03.2 Embolism following incomplete spontaneous abortion
  - O03.30 Unspecified complication following incomplete spontaneous abortion
  - O03.31 Shock following incomplete spontaneous abortion
  - o O03.32 Renal failure following incomplete spontaneous abortion
  - o O03.33 Metabolic disorder following incomplete spontaneous abortion
  - O03.34 Damage to pelvic organs following incomplete spontaneous abortion
  - O03.35 Other venous complications following incomplete spontaneous abortion
  - o 003.36 Cardiac arrest following incomplete spontaneous abortion
  - o 003.37 Sepsis following incomplete spontaneous abortion
  - o 003.38 Urinary tract infection following incomplete spontaneous abortion
  - o O03.39 Incomplete spontaneous abortion with other complications
  - $\circ$  O03.4 Incomplete spontaneous abortion without complication
  - O03.5 Genital tract and pelvic infection following complete or unspecified spontaneous abortion
  - O03.6 Delayed or excessive hemorrhage following complete or unspecified spontaneous abortion

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 61 of 148

- O03.7 Embolism following complete or unspecified spontaneous abortion
- O03.80 Unspecified complication following complete or unspecified spontaneous abortion
- O03.81 Shock following complete or unspecified spontaneous abortion
- O03.82 Renal failure following complete or unspecified spontaneous abortion
- O03.83 Metabolic disorder following complete or unspecified spontaneous abortion
- O03.84 Damage to pelvic organs following complete or unspecified spontaneous abortion
- O03.85 Other venous complications following complete or unspecified spontaneous abortion
- $\circ$  O03.86 Cardiac arrest following complete or unspecified spontaneous abortion
- o 003.87 Sepsis following complete or unspecified spontaneous abortion
- O03.88 Urinary tract infection following complete or unspecified spontaneous abortion
- O03.89 Complete or unspecified spontaneous abortion with other complications
- O03.9 Complete or unspecified spontaneous abortion without complication
- O31.1 Continuing pregnancy after spontaneous abortion of one fetus or more
- o O31.2 Continuing pregnancy after intrauterine death of one fetus or more
- o O36.4 Maternal care for intrauterine death
- CPT<sup>7</sup> 59800 Treatment of spontaneous abortion, first trimester
- CPT 59801 Treatment of spontaneous abortion, first trimester
- CPT 59810 Treatment of spontaneous abortion, second trimester
- CPT 59811 Treatment of spontaneous abortion, second trimester
- Stillbirth
  - $\circ$  O31.2 Continuing pregnancy after intrauterine death of one fetus or more
  - o 036.4 Maternal care for intrauterine death
  - P95 Stillbirth

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 62 of 148

<sup>&</sup>lt;sup>7</sup> CPT copyright 2022 American Medical Association. All rights reserved.

PFIZER CONFIDENTIAL

- Z37.1 Single stillbirth
- Z37.3 Twins, one liveborn and one stillborn
- $\circ$  Z37.4 Twins, both stillborn
- o Z37.60 Multiple births, unspecified, some liveborn
- o Z37.61 Triplets, some liveborn
- Z37.62 Quadruplets, some liveborn
- o Z37.63 Quintuplets, some liveborn
- o Z37.64 Sextuplets, some liveborn
- o Z37.69 Other multiple births, some liveborn
- Z37.7 Other multiple births, all stillborn
- Preterm birth
  - O60.1 Preterm labor with preterm delivery
  - P07.2 Extreme immaturity of newborn
  - o P07.3 Preterm [premature] newborn [other]
  - P07.30 Preterm newborn, unspecified weeks of gestation
  - o P07.31 Preterm newborn, gestational age 28 completed weeks
  - o P07.32 Preterm newborn, gestational age 29 completed weeks
  - P07.33 Preterm newborn, gestational age 30 completed weeks
  - o P07.34 Preterm newborn, gestational age 31 completed weeks
  - o P07.35 Preterm newborn, gestational age 32 completed weeks
  - $\circ \quad P07.36-Preterm \ newborn, \ gestational \ age \ 33 \ completed \ weeks$
  - o P07.37 Preterm newborn, gestational age 34 completed weeks
  - P07.38 Preterm newborn, gestational age 35 completed weeks
  - o P07.39 Preterm newborn, gestational age 36 completed weeks
- Small for gestational age
  - $\circ$  P05.10 to P05.19 Newborn small for gestational age
- Major congenital malformations

The following list of congenital malformation subcategories and codes is based on the EUROCAT Guide 1.4 dated 28 December 2018 (EUROCAT, 2020) and the New York State Department of Health Congenital Malformations Registry coding manual dated 22 October 2019 (New York State Department of Health Birth Defects Registry, 2021), consistent with those tracked by the Metropolitan Atlanta Congenital Defects Program (CDC, 2023a).

EUROCAT subgroups	ICD-10 code
All anomalies	Q-chapter, D21.5, D82.1, P35.0, P35.1, P37.1
Nervous system	Q00*, Q01*, Q02, Q03, Q04*, Q05*, Q06*, Q07**
Neural tube defects	Q00*, Q01*, Q05*
Anencephaly and similar malformations	Q00*
Encephalocele	Q01*
Spina bifida	Q05*
Hydrocephalus	Q03
Microcephaly	Q02
Arhinencephaly/holoprosencephaly	Q04.1, Q04.2
Eye	Q10*, Q11*, Q12*, Q13**, Q14*, Q15*
Anophthalmos/microphthalmos	Q11.0, Q11.1, Q11.2
Anophthalmos	Q11.0, Q11.1
Congenital cataract	Q12.0
Congenital glaucoma	Q15.0
Ear, face, and neck	Q16*-Q18*
Anotia	Q16.0
Circulatory System	Q20*, Q21*, Q22*, Q23*, Q24*, Q25**, Q26*,
	Q27**, Q28*
Severe congenital heart defects	Q20.0, Q20.1, Q20.3, Q20.4, Q21.2, Q21.3, Q22.0,
	Q22.4, Q22.5, Q22.6, Q23.0, Q23.2, Q23.3, Q23.4,
	Q25.1, Q25.2*, Q26.2
Common arterial truncus	Q20.0
Double outlet right ventricle	Q20.1
Transposition of great vessels	Q20.3
Single ventricle	Q20.4
Ventricular septal defect (VSD)	Q21.0
Atrial septal defect (ASD)	Q21.1
Atrioventricular septal defect (AVSD)	Q21.2
Tetralogy of Fallot	Q21.3
Tricuspid atresia and stenosis	Q22.4
Ebstein's anomaly	Q22.5
Pulmonary valve stenosis	Q22.1
Pulmonary valve atresia	Q22.0
Aortic valve atresia/stenosis	Q23.0
Mitral valve anomalies	Q23.2, Q23.3
Hypoplastic left heart	Q23.4
Hypoplastic right heart	Q22.6
Coarctation of aorta	Q25.1
Aortic atresia / interrupted aortic arch	Q25.2*
Total anomalous pulmonary venous return (TAPVR)	Q26.2
Patent ductus arteriosus (PDA) as only congenital	Q25.0
heart disease (CHD) in term infants (gestational age	
+37 weeks)	

EUROCAT subgroups	ICD-10 code
Respiratory	Q30*-Q34*
Choanal atresia	Q30.0
Cystic adenomatoid malformation of lung	Q33.0
EUROCAT subgroups	ICD-10 code
Oro-facial clefts	Q35*-Q37*
Cleft lip with or without cleft palate	Q36*, Q37*
Cleft palate	Q35*
Digestive system	Q38*-Q45*, Q79.0
Esophageal atresia with or without trachea-	Q39.0, Q39.1
esophageal fistula	
Duodenal atresia or stenosis	Q41.0
Atresia or stenosis of other parts of small intestine	Q41.1, Q41.2, Q41.8
Ano-rectal atresia and stenosis	Q42.0-Q42.3
Hirschsprung's disease	Q43.1
Atresia of bile ducts	Q44.2
Annular pancreas	Q45.1
Diaphragmatic hernia	Q79.0
Abdominal wall defects	Q79.2, Q79.3, Q79.5*
Gastroschisis	Q79.3
Omphalocele	Q79.2
Urinary	Q60*, Q61**, Q62**, Q63*, Q64**, Q79.4
Bilateral renal agenesis including Potter syndrome	Q60.1, Q60.6
Multicystic renal dysplasia	Q61.4
Congenital hydronephrosis	Q62.0
Bladder exstrophy and/or epispadias	Q64.0, Q64.1*
Posterior urethral valve and/or prune belly	Q64.2, Q79.4
Genital	Q50**, Q51***, Q52***, Q54*, Q55**, Q56*
Hypospadias	Q54*
Indeterminate sex	Q56*
Musculoskeletal	Q65**, Q66***, Q67*, Q68*, Q69*, Q70**,
	$Q/1^{***}, Q/2^{***}, Q/3^{*}, Q/4^{*}, Q/5^{*}, Q/6^{***}, Q/6^{****}, Q/6^{***}, Q/6^{**}, Q$
	Q//*, Q/8*, Q/9**
Limb reduction defects	Q/1***, Q/2***, Q/3*
Club foot – talipes equinovarus	Q66.0*
Hip dislocation and/or dysplasia	Q65.0*, Q65.1, Q65.2, Q65.80, Q65.81
Polydactyly	Q69*
Syndactyly	Q/0**
Stralatal dyamlaging	074.0 077* 078.0 078.2 078.9
Skeletal dysplastas	075.0
Congonital constriction hands/empiotic hand	070.8
Situa inversus	Q79.8
Conjoined twins	Q89.5
Congonital skin disorders	Q09.4 Q09.* Q02*
	087.2
I aterality anomalies	020.6 024.0 033.8 080.0 080.3
Teratogenic syndromes with malformations	Q20.0, Q24.0, Q35.0, Q07.0, Q07.5
Fetal alcohol syndrome	0860
Valproate syndrome	086.8
Maternal infections resulting in malformations	P35 0 P35 1 P37 1
Clett palate Digestive system Esophageal atresia with or without trachea- esophageal fistula Duodenal atresia or stenosis Atresia or stenosis of other parts of small intestine Ano-rectal atresia and stenosis Hirschsprung's disease Atresia of bile ducts Annular pancreas Diaphragmatic hernia Abdominal wall defects Gastroschisis Omphalocele Urinary Bilateral renal agenesis including Potter syndrome Multicystic renal dysplasia Congenital hydronephrosis Bladder exstrophy and/or epispadias Posterior urethral valve and/or prune belly Genital Hypospadias Indeterminate sex Musculoskeletal Limb reduction defects Club foot – talipes equinovarus Hip dislocation and/or dysplasia Polydactyly Syndactyly Other anomalies/syndromes Skeletal dysplasias Congenital skin disorders VATER/VACTERL Laterality anomalies Teratogenic syndrome Multorme Multormetions Fetal alcohol syndrome Multorme Multormetions	Q35*         Q38*-Q45*, Q79.0         Q39.0, Q39.1         Q41.0         Q41.1, Q41.2, Q41.8         Q42.0-Q42.3         Q44.2         Q45.1         Q79.2         Q79.3         Q79.2         Q60*, Q61**, Q62**, Q63*, Q64**, Q79.4         Q60.1, Q60.6         Q61.4         Q62.0         Q64.2, Q79.4         Q56*         Q64.2, Q79.4         Q56**, Q66***, Q67*, Q68*, Q69*, Q70**, Q71***, Q71***, Q72***, Q73*, Q74*, Q75*, Q76***, Q77*, Q78*, Q79**         Q71***, Q72***, Q73*, Q74*, Q75*, Q76***, Q77*, Q78*, Q79**         Q71***, Q72***, Q73*, Q74*, Q75*, Q76***, Q71***, Q71***, Q72***, Q73*, Q74*, Q75*, Q76***, Q71***, Q72***, Q73*, Q74*, Q75*, Q76***, Q71***, Q71***, Q72***, Q73*, Q74*, Q75*, Q76***, Q71***, Q72***, Q73*, Q74*, Q75*, Q76***, Q71***, Q72***, Q73*, Q66.0*         Q60*       Q60*         Q70**       Q74.0, Q77*, Q78.0, Q78.2-Q78.8         Q75.0       Q79.8         Q89.3       Q89.4         Q89.4       Q80*-Q82*         Q87.2       Q20.6, Q24.0, Q33.8, Q89.0, Q89.3         Q86.4       Q86.0         Q86.6       Q86.8         P35.0, P35.1, P37.1       Q86.9

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 65 of 148

EUROCAT subgroups	ICD-10 code
Genetic syndromes and microdeletions	Q44.7, Q61.9, Q74.8, Q75.1, Q75.4, Q75.8, Q87**, Q93.51, D82.1

\* Indicates how many additional decimal places may be included though not required in the wildcard, including the number listed. For instance, Q93\*\* should include the following: Q93 (non-billable), Q93.0, Q93.1, Q93.2, Q93.3, Q93.4, Q93.5 (non-billable), Q93.51, Q93.59, Q93.7, Q93.8 (non-billable), Q93.81, Q93.82, Q93.88, Q93.89, Q93.9. Chromosomal disorders are not included in the outcomes of interest

#### 15.4. Appendix IV – Covariate Codes

#### 15.4.1. Comorbidities

#### 15.4.1.1. Asthma

#### 15.4.1.1.1. ICD-10-CM Codes

J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma
J82.83	Eosinophilic asthma

# 15.4.1.2. Non-Malignant Blood Disorders

#### 15.4.1.2.1. ICD-10-CM Codes

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 67 of 148

D55.1	Anemia due to other disorders of glutathione metabolism
D55.21	Anemia due to pyruvate kinase deficiency
D55.29	Anemia due to other disorders of glycolytic enzymes
D55.3	Anemia due to disorders of nucleotide metabolism
D55.8	Other anemias due to enzyme disorders
D55.9	Anemia due to enzyme disorder, unspecified
D56.0	Alpha thalassemia
D56.1	Beta thalassemia
D56.2	Delta-beta thalassemia
D56.3	Thalassemia minor
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]
D56.5	Hemoglobin E-beta thalassemia
D56.8	Other thalassemias
D56.9	Thalassemia, unspecified
D57.00	Hb-SS disease w/ crisis, unspecified
D57.01	Hb-SS disease w/ acute chest syndrome
D57.02	Hb-SS disease w/ splenic sequestration
D57.03	Hb-SS disease with cerebral vascular involvement
D57.04	Hb-SS disease with dactylitis
D57.09	Hb-SS disease with crisis with other specified complication
D57.1	Sickle cell disease w/o crisis
D57.20	Sickle cell/Hb-C disease w/o crisis
D57.21	Sickle cell/Hb-C disease w/ crisis
D57.211	Sickle cell/Hb-C disease w/ acute chest syndrome

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 68 of 148

D57.212	Sickle cell/Hb-C disease w/ splenic sequestration
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement
D57.214	Sickle-cell/Hb-C disease with dactylitis
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication
D57.219	Sickle cell/Hb-C disease w/ crisis, unspecified
D57.3	Sickle cell trait
D57.40	Sickle cell thalassemia w/o crisis
D57.41	Sickle-cell thalassemia w/ crisis
D57.411	Sickle cell thalassemia w/ acute chest syndrome
D57.412	Sickle cell thalassemia w/ splenic sequestration
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication
D57.419	Sickle cell thalassemia w/ crisis, unspecified
D57.42	Sickle-cell thalassemia beta zero without crisis
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement
D57.434	Sickle-cell thalassemia beta zero with dactylitis
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified

D57.44	Sickle-cell thalassemia beta plus without crisis
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration
D57.454	Sickle-cell thalassemia beta plus with dactylitis
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified
D57.80	Other sickle cell disorders w/o crisis
D57.811	Other sickle cell disorders w/ acute chest syndrome
D57.812	Other sickle cell disorders w/ splenic sequestration
D57.813	Other sickle-cell disorders with cerebral vascular involvement
D57.814	Other sickle-cell disorders with dactylitis
D57.818	Other sickle-cell disorders with crisis with other specified complication
D57.819	Other sickle cell disorders w/ crisis, unspecified
D58.0	Hereditary spherocytosis
D58.1	Hereditary elliptocytosis
D58.2	Other hemoglobinopathies
D58.8	Other specified hereditary hemolytic anemias
D58.9	Hereditary hemolytic anemia, unspecified
D59.0	Drug-induced autoimmune hemolytic anemia
D59.10	Autoimmune hemolytic anemia, unspecified
D59.11	Warm autoimmune hemolytic anemia
D59.12	Cold autoimmune hemolytic anemia
D59.13	Mixed type autoimmune hemolytic anemia

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 70 of 148

D59.19	Other autoimmune hemolytic anemia
D59.2	Drug-induced nonautoimmune hemolytic anemia
D59.30	Hemolytic-uremic syndrome, unspecified
D59.31	Infection-associated hemolytic-uremic syndrome
D59.32	Hereditary hemolytic-uremic syndrome
D59.39	Other hemolytic-uremic syndrome
D59.4	Other nonautoimmune hemolytic anemias
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]
D59.6	Hemoglobinuria due to hemolysis from other external causes
D59.8	Other acquired hemolytic anemias
D59.9	Acquired hemolytic anemia, unspecified
D60.0	Chronic acquired pure red cell aplasia
D60.1	Transient acquired pure red cell aplasia
D60.8	Other acquired pure red cell aplasias
D60.9	Acquired pure red cell aplasia, unspecified
D61.01	Constitutional (pure) red blood cell aplasia
D61.02	Shwachman-Diamond syndrome
D61.09	Other constitutional aplastic anemia
D61.1	Drug-induced aplastic anemia
D61.2	Aplastic anemia due to other external agents
D61.3	Idiopathic aplastic anemia
D61.810	Antineoplastic chemotherapy induced pancytopenia
D61.811	Other drug-induced pancytopenia

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 71 of 148

D61.82	Myelophthisis
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes
D61.9	Aplastic anemia, unspecified
D62	Acute posthemorrhagic anemia
D63.0	Anemia in neoplastic disease
D63.1	Anemia in chronic kidney disease
D63.8	Anemia in other chronic diseases classified elsewhere
D64.0	Hereditary sideroblastic anemia
D64.1	Secondary sideroblastic anemia due to disease
D64.2	Secondary sideroblastic anemia due to drugs and toxins
D64.3	Other sideroblastic anemias
D64.4	Congenital dyserythropoietic anemia
D64.81	Anemia due to antineoplastic chemotherapy
D64.89	Other specified anemias
D64.9	Anemia, unspecified
D65	Disseminated intravascular coagulation
D66	Hereditary factor VIII deficiency
D67	Hereditary factor IX deficiency
D68.00	Von Willebrand disease, unspecified
D68.1	Hereditary factor XI deficiency
D68.01	Von Willebrand disease, type 1
D68.020	Von Willebrand disease, type 2A
D68.021	Von Willebrand disease, type 2B

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 72 of 148
D68.022	Von Willebrand disease, type 2M
D68.023	Von Willebrand disease, type 2N
D68.029	Von Willebrand disease, type 2, unspecified
D68.03	Von Willebrand disease, type 3
D68.04	Acquired von Willebrand disease
D68.09	Other von Willebrand disease
D68.1	Hereditary factor XI deficiency
D68.2	Hereditary deficiency of other clotting factors
D68.311	Acquired hemophilia
D68.312	Antiphospholipid antibody with hemorrhagic disorder
D68.318	Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
D68.32	Hemorrhagic disorder due to extrinsic circulating anticoagulants
D68.4	Acquired coagulation factor deficiency
D68.51	Activated protein C resistance
D68.52	Prothrombin gene mutation
D68.59	Other primary thrombophilia
D68.61	Antiphospholipid syndrome
D68.62	Lupus anticoagulant syndrome
D68.69	Other thrombophilia
D68.8	Other specified coagulation defects
D68.9	Coagulation defect, unspecified
D69.0	Allergic purpura

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 73 of 148

D69.1	Qualitative platelet defects
D69.2	Other nonthrombocytopenic purpura
D69.3	Immune thrombocytopenic purpura
D69.41	Evans syndrome
D69.42	Congenital and hereditary thrombocytopenia purpura
D69.49	Other primary thrombocytopenia
D69.51	Post-transfusion purpura
D69.59	Other secondary thrombocytopenia
D69.6	Thrombocytopenia, unspecified
D69.8	Other specified hemorrhagic conditions
D69.9	Hemorrhagic condition, unspecified
D70.0	Congenital agranulocytosis
D70.1	Agranulocytosis secondary to cancer chemotherapy
D70.2	Other drug-induced agranulocytosis
D70.3	Neutropenia due to infection
D70.4	Cyclic neutropenia
D70.8	Other neutropenia
D70.9	Neutropenia, unspecified,
D71	Functional disorders of polymorphonuclear neutrophils
D72.0	Genetic anomalies of leukocytes
D72.10	Eosinophilia, unspecified
D72.110	Idiopathic hypereosinophilic syndrome [IHES]
D72.111	Lymphocytic Variant Hypereosinophilic Syndrome [LHES]
D72.118	Other hypereosinophilic syndrome

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 74 of 148

D72.119	Hypereosinophilic syndrome [HES], unspecified
D72.12	Drug rash with eosinophilia and systemic symptoms syndrome
D72.18	Eosinophilia in diseases classified elsewhere
D72.19	Other eosinophilia
D72.810	Lymphocytopenia
D72.818	Other decreased white blood cell count
D72.819	Decreased white blood cell count, unspecified
D72.820	Lymphocytosis (symptomatic)
D72.821	Monocytosis (symptomatic)
D72.822	Plasmacytosis
D72.823	Leukemoid reaction
D72.824	Basophilia
D72.825	Bandemia
D72.828	Other elevated white blood cell count
D72.829	Elevated white blood cell count, unspecified
D72.89	Other specified disorders of white blood cells
D72.9	Disorder of white blood cells, unspecified

# 15.4.1.3. Chronic Lung Disease

# 15.4.1.3.1. ICD-10-CM Codes

P27.0	Wilson-Mikity syndrome
P27.1	Bronchopulmonary dysplasia originating in the perinatal period
P27.8	Other chronic respiratory diseases originating in the perinatal period
P27.9 period	Unspecified chronic respiratory disease originating in the perinatal
E84.0	Cystic fibrosis with pulmonary manifestations

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 75 of 148

E84.11	Meconium ileus in cystic fibrosis
E84.19	Cystic fibrosis with other intestinal manifestations
E84.8	Cystic fibrosis with other manifestations
E84.9	Cystic fibrosis, unspecified
I27.0	Primary pulmonary hypertension
I27.1	Kyphoscoliotic heart disease
I27.20	Pulmonary hypertension, unspecified
I27.21	Secondary pulmonary arterial hypertension
I27.22	Pulmonary hypertension due to left heart disease
I27.23	Pulmonary hypertension due to lung diseases and hypoxia
I27.24	Chronic thromboembolic pulmonary hypertension
I27.29	Other secondary pulmonary hypertension
I27.81	Cor pulmonale (chronic)
I27.82	Chronic pulmonary embolism
I27.83	Eisenmenger's syndrome
I27.89	Other specified pulmonary heart diseases
I27.9	Pulmonary heart disease, unspecified
I28.0	Arteriovenous fistula of pulmonary vessels
I28.1	Aneurysm of pulmonary artery
I28.8	Other diseases of pulmonary vessels
I28.9	Disease of pulmonary vessels, unspecified
J41	Simple and mucopurulent chronic bronchitis
J41.0	Simple chronic bronchitis

J41.1 Mucopurulent chronic bronchitis

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 76 of 148

0,	0, 12 December 2023		
	J41.8	Mixed simple and mucopurulent chronic bronchitis	
	J42	Unspecified chronic bronchitis	
	J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	
	J43.1	Panlobular emphysema	
	J43.2	Centrilobular emphysema	
	J43.8	Other emphysema	
	J43.9	Emphysema, unspecified	
	J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	
	J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	
	J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	
	J44.89	Other specified chronic obstructive pulmonary disease	
	J44.9	Chronic obstructive pulmonary disease, unspecified	
	J60	Coal worker's pneumoconiosis	
	J61	Pneumoconiosis due to asbestos and other mineral fibers	
	J62.0	Pneumoconiosis due to talc dust	
	J62.8	Pneumoconiosis due to other dust containing silica	
	J63.0	Aluminosis (of lung)	
	J63.1	Bauxite fibrosis (of lung)	

- J63.2 Berylliosis
- J63.3 Graphite fibrosis (of lung)
- J63.4 Siderosis
- J63.5 Stannosis
- J63.6 Pneumoconiosis due to other specified inorganic dusts

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 77 of 148

J64	Unspecified pneumoconiosis
J65	Pneumoconiosis associated with tuberculosis
J66.0	Byssinosis
J66.1	Flax-dressers' disease
J66.2	Cannabinosis
J66.8	Airway disease due to other specific organic dusts
J67	Hypersensitivity pneumonitis due to organic dust
J67.0	Farmer's lung
J67.1	Bagassosis
J67.2	Bird fancier's lung
J67.3	Suberosis
J67.4	Maltworker's lung
J67.5	Mushroom-worker's lung
J67.6	Maple-bark-stripper's lung
J67.7	Air conditioner and humidifier lung
J67.8	Hypersensitivity pneumonitis due to other organic dusts
J67.9	Hypersensitivity pneumonitis due to unspecified organic dust
J68.4 vapors	Chronic respiratory conditions due to chemicals, gases, fumes and
J68.8	Other respiratory conditions due to chemicals, gases, fumes and vapors
J68.9 vapors	Unspecified respiratory condition due to chemicals, gases, fumes and
J70.1	Chronic and other pulmonary manifestations due to radiation
J70.3	Chronic drug-induced interstitial lung disorders
J70.5	Respiratory conditions due to smoke inhalation

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 78 of 148

- J81.1 Chronic pulmonary edema J82.81 Chronic eosinophilic pneumonia J84.01 Alveolar proteinosis J84.02 Pulmonary alveolar microlithiasis J84.03 Idiopathic pulmonary hemosiderosis J84.09 Other alveolar and parieto-alveolar conditions J84.10 Pulmonary fibrosis, unspecified J84.111 Idiopathic interstitial pneumonia, not otherwise specified J84.112 Idiopathic pulmonary fibrosis J84.113 Idiopathic non-specific interstitial pneumonitis J84.115 Respiratory bronchiolitis interstitial lung disease J84.116 Cryptogenic organizing pneumonia J84.117 Desquamative interstitial pneumonia Interstitial lung disease with progressive fibrotic phenotype in diseases J84.170 classified elsewhere J84.178 Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere J84.2 Lymphoid interstitial pneumonia J84.81 Lymphangioleiomyomatosis J84.82 Adult pulmonary Langerhans cell histiocytosis J84.83 Surfactant mutations of the lung J84.841 Neuroendocrine cell hyperplasia of infancy
  - J84.842 Pulmonary interstitial glycogenosis
  - J84.843 Alveolar capillary dysplasia with vein misalignment
  - J84.848 Other interstitial lung diseases of childhood

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 79 of 148

J84.89	Other specified	l interstitial	pulmonary	diseases

- J84.9 Interstitial pulmonary disease, unspecified
- Z77.090 Contact with and (suspected) exposure to asbestos
- J85.0 Gangrene and necrosis of lung
- J93.81 Chronic pneumothorax

### 15.4.1.4. Down Syndrome

#### 15.4.1.4.1. ICD-10-CM Codes

- Q90.0 Trisomy 21, nonmosaicism (meiotic nondisjunction)
- Q90.1 Trisomy 21, mosaicism (mitotic nondisjunction)
- Q90.2 Trisomy 21, translocation
- Q90.9 Down syndrome, unspecified

#### 15.4.1.5. Heart Disease

### 15.4.1.5.1. ICD-10-CM Codes

- I01.0 Acute rheumatic pericarditis
- I01.1 Acute rheumatic endocarditis
- I01.2 Acute rheumatic myocarditis
- I01.8 Other acute rheumatic heart disease
- I01.9 Acute rheumatic heart disease, unspecified
- I02.0 Rheumatic chorea with heart involvement
- I05.0 Rheumatic mitral stenosis
- I05.1 Rheumatic mitral insufficiency
- I05.2 Rheumatic mitral stenosis with insufficiency
- I05.8 Other rheumatic mitral valve diseases
- I05.9 Rheumatic mitral valve disease, unspecified
- I06.0 Rheumatic aortic stenosis

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 80 of 148

I06.1	Rheumatic aortic insufficiency
I06.2	Rheumatic aortic stenosis with insufficiency
I07.0	Rheumatic tricuspid stenosis
I07.1	Rheumatic tricuspid insufficiency
I07.2	Rheumatic tricuspid stenosis and insufficiency
I07.8	Other rheumatic tricuspid valve diseases
I07.9	Rheumatic tricuspid valve disease, unspecified
I06.8	Other rheumatic aortic valve diseases
I06.9	Rheumatic aortic valve disease, unspecified
I08.0	Rheumatic disorders of both mitral and aortic valves
I08.1	Rheumatic disorders of both mitral and tricuspid valves
I08.2	Rheumatic disorders of both aortic and tricuspid valves
I08.3	Combined rheumatic disorders of mitral, aortic and tricuspid valves
I08.8	Other rheumatic multiple valve diseases
I08.9	Rheumatic multiple valve disease, unspecified
I09.0	Rheumatic myocarditis
I09.1	Rheumatic diseases of endocardium, valve unspecified
I09.2	Chronic rheumatic pericarditis
I09.81	Rheumatic heart failure
I09.89	Other specified rheumatic heart diseases

- I09.9 Rheumatic heart disease, unspecified
- I11.0 Hypertensive heart disease with heart failure
- I11.9 Hypertensive heart disease without heart failure

- I13.0 Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease
- I13.10 Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease
- I13.11 Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease
- I13.2 Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease
- I20.0 Unstable angina
- I20.1 Angina pectoris with documented spasm
- I20.8 Other forms of angina pectoris
- I21.01 ST elevation (STEMI) myocardial infarction involving left main coronary artery
- I21.02 ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
- I21.09 ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
- I21.11 ST elevation (STEMI) myocardial infarction involving right coronary artery
- I21.19 ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
- I21.21 ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
- I21.29 ST elevation (STEMI) myocardial infarction involving other sites
- I21.3 ST elevation (STEMI) myocardial infarction of unspecified site
- I21.4 Non-ST elevation (NSTEMI) myocardial infarction
- I21.9 Acute myocardial infarction, unspecified
- I21.A1 Myocardial infarction type 2

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 82 of 148

I21.A9	Other myocardial infarction type
I22.0 wall	Subsequent ST elevation (STEMI) myocardial infarction of anterior
I22.1 wall	Subsequent ST elevation (STEMI) myocardial infarction of inferior
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites
I22.9 unspecifie	Subsequent ST elevation (STEMI) myocardial infarction of d site
I23.0	Hemopericardium as current complication following acute myocardial infarction
I23.1	Atrial septal defect as current complication following acute myocardial infarction
I23.2	Ventricular septal defect as current complication following acute myocardial infarction
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction
I23.7	Postinfarction angina
I23.8	Other current complications following acute myocardial infarction
I24.0	Acute coronary thrombosis not resulting in myocardial infarction
I24.1	Dressler's syndrome
I24.8	Other forms of acute ischemic heart disease
I24.9	Acute ischemic heart disease, unspecified

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023

I25.10 pectoris	Atherosclerotic heart disease of native coronary artery without angina
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
I25.3	Aneurysm of heart
I25.41	Coronary artery aneurysm
I25.42	Coronary artery dissection
I25.5	Ischemic cardiomyopathy
I25.6	Silent myocardial ischemia
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm
125.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris
125.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris

- I25.719 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris I25.720 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris I25.721 Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm I25.728 Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris 125.729 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris I25.730 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris I25.731 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm 125.738 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris I25.739 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris I25.750 Atherosclerosis of native coronary artery of transplanted heart with unstable angina I25.751 Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm
- I25.758 Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris
- I25.759 Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
- I25.760 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina
- I25.761 Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm

- I25.768 Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris I25.769 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris I25.790 Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris I25.791 Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm I25.798 Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris I25.799 Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris I25.810 Atherosclerosis of coronary artery bypass graft(s) without angina pectoris I25.811 Atherosclerosis of native coronary artery of transplanted heart without angina pectoris I25.812 Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris 125.82 Chronic total occlusion of coronary artery I25.83 Coronary atherosclerosis due to lipid rich plaque
  - I25.84 Coronary atherosclerosis due to calcified coronary lesion
  - I25.89 Other forms of chronic ischemic heart disease
  - I25.9 Chronic ischemic heart disease, unspecified
  - I26.01 Septic pulmonary embolism with acute cor pulmonale
  - I26.02 Saddle embolus of pulmonary artery with acute cor pulmonale
  - I26.09 Other pulmonary embolism with acute cor pulmonale
  - I27.1 Kyphoscoliotic heart disease
  - I27.22 Pulmonary hypertension due to left heart disease

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 86 of 148

I27.81	Cor pulmonale (chronic)
I27.83	Eisenmenger's syndrome
I27.9	Pulmonary heart disease, unspecified
130.0	Acute nonspecific idiopathic pericarditis
I30.1	Infective pericarditis
130.8	Other forms of acute pericarditis
130.9	Acute pericarditis, unspecified
I31.0	Chronic adhesive pericarditis
I31.1	Chronic constrictive pericarditis
I31.2	Hemopericardium, not elsewhere classified
I31.3	Pericardial effusion (noninflammatory)
I31.4	Cardiac tamponade
I31.8	Other specified diseases of pericardium
I31.9	Disease of pericardium, unspecified
I33.0	Acute and subacute infective endocarditis
I33.9	Acute and subacute endocarditis, unspecified
I34.0	Nonrheumatic mitral (valve) insufficiency
I34.1	Nonrheumatic mitral (valve) prolapse
I34.2	Nonrheumatic mitral (valve) stenosis
I34.8	Other nonrheumatic mitral valve disorders
I34.9	Nonrheumatic mitral valve disorder, unspecified
I35.0	Nonrheumatic aortic (valve) stenosis
I35.1	Nonrheumatic aortic (valve) insufficiency

I35.2 Nonrheumatic aortic (valve) stenosis with insufficiency

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 87 of 148

- I35.8 Other nonrheumatic aortic valve disorders
- I35.9 Nonrheumatic aortic valve disorder, unspecified
- I36.0 Nonrheumatic tricuspid (valve) stenosis
- I36.1 Nonrheumatic tricuspid (valve) insufficiency
- I36.2 Nonrheumatic tricuspid (valve) stenosis with insufficiency
- I36.8 Other nonrheumatic tricuspid valve disorders
- I36.9 Nonrheumatic tricuspid valve disorder, unspecified
- I37.0 Nonrheumatic pulmonary valve stenosis
- I37.1 Nonrheumatic pulmonary valve insufficiency
- I37.2 Nonrheumatic pulmonary valve stenosis with insufficiency
- I37.8 Other nonrheumatic pulmonary valve disorders
- I37.9 Nonrheumatic pulmonary valve disorder, unspecified
- I38 Endocarditis, valve unspecified
- I39 Endocarditis and heart valve disorders in diseases classified elsewhere
- I40.0 Infective myocarditis
- I40.1 Isolated myocarditis
- I40.8 Other acute myocarditis
- I40.9 Acute myocarditis, unspecified
- I41 Myocarditis in diseases classified elsewhere
- I42.0 Dilated cardiomyopathy
- I42.1 Obstructive hypertrophic cardiomyopathy
- I42.2 Other hypertrophic cardiomyopathy
- I42.3 Endomyocardial (eosinophilic) disease
- I42.4 Endocardial fibroelastosis

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 88 of 148

I42.5	Other restrictive cardiomyopathy
I42.6	Alcoholic cardiomyopathy
I42.7	Cardiomyopathy due to drug and external agent
I42.8	Other cardiomyopathies
I42.9	Cardiomyopathy, unspecified
I43	Cardiomyopathy in diseases classified elsewhere
I44.0	Atrioventricular block, first degree
I44.1	Atrioventricular block, second degree
I44.2	Atrioventricular block, complete
I44.3	Other and unspecified atrioventricular block
I44.30	Unspecified atrioventricular block
I44.39	Other atrioventricular block
I44.4	Left anterior fascicular block
I44.5	Left posterior fascicular block
I44.60	Unspecified fascicular block
I44.69	Other fascicular block
I44.7	Left bundle-branch block, unspecified
I45.0	Right fascicular block
I45.10	Unspecified right bundle-branch block
I45.19	Other right bundle-branch block
I45.2	Bifascicular block

- I45.3 Trifascicular block
- I45.4 Nonspecific intraventricular block
- I45.5 Other specified heart block

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 89 of 148

I45.6	Pre-excitation syndrome
I45.81	Long QT syndrome
I45.89	Other specified conduction disorders
I45.9	Conduction disorder, unspecified
I46.2	Cardiac arrest due to underlying cardiac condition
I46.8	Cardiac arrest due to other underlying condition
I46.9	Cardiac arrest, cause unspecified
I47.0	Re-entry ventricular arrhythmia
I47.1	Supraventricular tachycardia
I47.2	Ventricular tachycardia
I47.9	Paroxysmal tachycardia, unspecified
I48.0	Paroxysmal atrial fibrillation
I48.11	Longstanding persistent atrial fibrillation
I48.19	Other persistent atrial fibrillation
I48.20	Chronic atrial fibrillation, unspecified
I48.21	Permanent atrial fibrillation
I48.3	Typical atrial flutter
I48.4	Atypical atrial flutter
I48.91	Unspecified atrial fibrillation
I48.92	Unspecified atrial flutter
I49.01	Ventricular fibrillation
I49.02	Ventricular flutter
I49.1	Atrial premature depolarization
I49.2	Junctional premature depolarization

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 90 of 148

- I49.3Ventricular premature depolarization
- I49.40 Unspecified premature depolarization
- I49.49 Other premature depolarization
- I49.5 Sick sinus syndrome
- I49.8 Other specified cardiac arrhythmias
- I49.9 Cardiac arrhythmia, unspecified
- I50.1 Left ventricular failure, unspecified
- I50.21 Acute systolic (congestive) heart failure
- I50.22 Chronic systolic (congestive) heart failure
- I50.23 Acute on chronic systolic (congestive) heart failure
- I50.30 Unspecified diastolic (congestive) heart failure
- I50.31 Acute diastolic (congestive) heart failure
- I50.32 Chronic diastolic (congestive) heart failure
- I50.33 Acute on chronic diastolic (congestive) heart failure
- I50.40 Unspecified combined systolic (congestive) and diastolic (congestive) heart failure
- I50.41 Acute combined systolic (congestive) and diastolic (congestive) heart failure
- I50.42 Chronic combined systolic (congestive) and diastolic (congestive) heart failure
- I50.43 Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure
- I50.810 Right heart failure, unspecified
- I50.811 Acute right heart failure
- I50.812 Chronic right heart failure
- I50.813 Acute on chronic right heart failure

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 91 of 148

- I50.814 Right heart failure due to left heart failure
- I50.82 Biventricular heart failure
- I50.83 High output heart failure
- I50.84 End stage heart failure
- I50.89 Other heart failure
- I50.9 Heart failure, unspecified
- I51.0 Cardiac septal defect, acquired
- I51.1 Rupture of chordae tendineae, not elsewhere classified
- I51.2 Rupture of papillary muscle, not elsewhere classified
- I51.3 Intracardiac thrombosis, not elsewhere classified
- I51.4 Myocarditis, unspecified
- I51.5 Myocardial degeneration
- I51.7 Cardiomegaly
- I51.81 Takotsubo syndrome
- I51.89 Other ill-defined heart diseases
- I51.9 Heart disease, unspecified
- I52 Other heart disorders in diseases classified elsewhere

## 15.4.1.6. History of COVID-19

## 15.4.1.6.1. ICD-10-CM Codes

- U07.1 COVID-19, virus identified
- B97.29 Other coronavirus as the cause of diseases classified elsewhere
- J12.82 Pneumonia due to coronavirus disease 2019
- Z86.16 Personal history of COVID-19

### 15.4.1.7. Immunocompromised Status

### 15.4.1.7.1. ICD-10-CM Codes

D80.0 Hereditary hypogammaglobulinemia Nonfamilial hypogammaglobulinemia D80.1 D80.2 Selective deficiency of immunoglobulin A [IgA] D80.3 Selective deficiency of immunoglobulin G [IgG] subclasses D80.4 Selective deficiency of immunoglobulin M [IgM] D80.5 Immunodeficiency with increased immunoglobulin M [IgM] D80.6 Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia D80.7 Transient hypogammaglobulinemia of infancy D80.8 Other immunodeficiencies with predominantly antibody defects D80.9 Immunodeficiency with predominantly antibody defects, unspecified D81.0 Severe combined immunodeficiency [SCID] with reticular dysgenesis D81.1 Severe combined immunodeficiency [SCID] with low T- and B-cell numbers D81.2 Severe combined immunodeficiency [SCID] with low or normal B-cell numbers D81.30 Adenosine deaminase deficiency, unspecified D81.31 Severe combined immunodeficiency due to adenosine deaminase deficiency D81.32 Adenosine deaminase 2 deficiency D81.39 Other adenosine deaminase deficiency D81.4 Nezelof's syndrome D81.5 Purine nucleoside phosphorylase [PNP] deficiency D81.6 Major histocompatibility complex class I deficiency

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 93 of 148

- D81.7 Major histocompatibility complex class II deficiency
- D81.8 Other combined immunodeficiencies
- D81.81 Biotin-dependent carboxylase deficiency
- D81.810 Biotinidase deficiency
- D81.818 Other biotin-dependent carboxylase deficiency
- D81.819 Biotin-dependent carboxylase deficiency, unspecified
- D81.89 Other combined immunodeficiencies
- D81.9 Combined immunodeficiency, unspecified
- D82.0 Wiskott-Aldrich syndrome
- D82.1 Di George's syndrome
- D82.2 Immunodeficiency with short-limbed stature
- D82.3 Immunodeficiency following hereditary defective response to Epstein-Barr virus
- D82.4 Hyperimmunoglobulin E [IgE] syndrome
- D82.8 Immunodeficiency associated with other specified major defects
- D82.9 Immunodeficiency associated with major defect, unspecified
- D83 Common variable immunodeficiency
- D83.0 Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
- D83.1 Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
- D83.2 Common variable immunodeficiency with autoantibodies to B- or Tcells
- D83.8 Other common variable immunodeficiencies
- D83.9 Common variable immunodeficiency, unspecified
- D84.0 Lymphocyte function antigen-1 [LFA-1] defect

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 94 of 148

- D84.1 Defects in the complement system D84.8 Other specified immunodeficiencies Immunodeficiency, unspecified D84.9 B20 Human immunodeficiency virus [HIV] disease Z21 Asymptomatic human immunodeficiency virus [HIV] infection status O98.7 Human immunodeficiency virus [HIV] disease complicating pregnancy, childbirth and the puerperium B97.35 Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere Z94.0 Kidney transplant status Z94.1 Heart transplant status Z94.2 Lung transplant status Z94.3 Heart and lungs transplant status Z94.4 Liver transplant status Z94.5 Skin transplant status Z94.6 Bone transplant status Z94.7 Corneal transplant status Z94.81 Bone marrow transplant status Z94.82 Intestine transplant status Z94.83 Pancreas transplant status Z94.84 Stem cells transplant status
  - Z94.89Other transplanted organ and tissue status
  - Z94.9 Transplanted organ and tissue status, unspecified

## 15.4.1.7.2. CPT Codes<sup>8</sup>

33935	Heart-lung transp	lant with recipie	nt cardiectomy-	pneumonectomy
	<u> </u>		~ ~ ~	

- 33945 Heart transplant, with or without recipient cardiectomy
- 80158 Cyclosporine
- 80197 Tacrolimus
- 80195 Sirolimus
- 80180 Mycophenolate (mycophenolic acid)

### 15.4.1.7.3. HCPCS Codes

J0485	Injection, belatacept, 1 mg
J7500	Azathioprine, oral, 50 mg
J7501	Azathioprine, parenteral, 100 mg
J7502	Cyclosporine, oral, 100 mg
J7503	Tacrolimus, extended release, (Envarsus XR), oral, 0.25 mg
J7504	Lymphocyte immune globulin, antithymocyte globulin, equine, parenteral, 250 mg
J7505	Muromonab-CD3, parenteral, 5 mg
J7507	Tacrolimus, immediate release, oral, 1 mg
J7508	Tacrolimus, extended release, (Astagraf XL), oral, 0.1 mg
J7509	Methylprednisolone oral, per 4 mg
J7510	Prednisolone oral, per 5 mg
J7511	Lymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg

- J7512 Prednisone, immediate release or delayed release, oral, 1 mg
- J7513 Daclizumab, parenteral, 25 mg

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 96 of 148

<sup>&</sup>lt;sup>8</sup> CPT copyright 2022 American Medical Association. All rights reserved.

J7515	Cyclosporine, oral, 25 mg
J7516	Cyclosporin, parenteral, 250 mg
J7517	Mycophenolate mofetil, oral, 250 mg
J7518	Mycophenolic acid, oral, 180 mg
J7519	Injection, mycophenolate mofetil, 10 mg
J7520	Sirolimus, oral, 1 mg
J7525	Tacrolimus, parenteral, 5 mg
J7527	Everolimus, oral, 0.25 mg
J7599	Immunosuppressive drug, not otherwise classified
J8530	Cyclophosphamide; oral, 25 mg
J8610	Methotrexate; oral, 2.5 mg

## 15.4.1.7.4. NDC Codes

NDC codes corresponding to the above immunosuppressant medications will be utilized where applicable.

# 15.4.1.8. Kidney Disorders

## 15.4.1.8.1. ICD-10-CM Codes

N00.0	Acute nephritic syndrome with minor glomerular abnormality
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions
N00.2 glomerulo	Acute nephritic syndrome with diffuse membranous nephritis
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis
N00.5 glomerulo	Acute nephritic syndrome with diffuse mesangiocapillary nephritis
N00.6	Acute nephritic syndrome with dense deposit disease
	PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 97 of 148

- N00.7 Acute nephritic syndrome with diffuse crescentic glomerulonephritis
- N00.8 Acute nephritic syndrome with other morphologic changes
- N00.9 Acute nephritic syndrome with unspecified morphologic changes

N01.0 Rapidly progressive nephritic syndrome with minor glomerular abnormality

- N01.1 Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions
- N01.2 Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis
- N01.3 Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
- N01.4 Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis
- N01.5 Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
- N01.6 Rapidly progressive nephritic syndrome with dense deposit disease
- N01.7 Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis

N01.8 Rapidly progressive nephritic syndrome with other morphologic changes

- N01.9 Rapidly progressive nephritic syndrome with unspecified morphologic changes
- N02.0 Recurrent and persistent hematuria with minor glomerular abnormality
- N02.1 Recurrent and persistent hematuria with focal and segmental glomerular lesions
- N02.2 Recurrent and persistent hematuria with diffuse membranous glomerulonephritis
- N02.3 Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis

N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis
N02.6	Recurrent and persistent hematuria with dense deposit disease
N02.7 glomerulo	Recurrent and persistent hematuria with diffuse crescentic nephritis
N02.8	Recurrent and persistent hematuria with other morphologic changes
N02.9 changes	Recurrent and persistent hematuria with unspecified morphologic
N03.0	Chronic nephritic syndrome with minor glomerular abnormality
N03.1 lesions	Chronic nephritic syndrome with focal and segmental glomerular
N03.2 glomerulo	Chronic nephritic syndrome with diffuse membranous nephritis
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
N03.6	Chronic nephritic syndrome with dense deposit disease
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis
N03.8	Chronic nephritic syndrome with other morphologic changes
N03.9	Chronic nephritic syndrome with unspecified morphologic changes
N04.0	Nephrotic syndrome with minor glomerular abnormality
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis

N04.3 Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis

N04.4 Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis

N04.5 Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis

- N04.6 Nephrotic syndrome with dense deposit disease
- N04.7 Nephrotic syndrome with diffuse crescentic glomerulonephritis
- N04.8 Nephrotic syndrome with other morphologic changes
- N04.9 Nephrotic syndrome with unspecified morphologic changes
- N05.0 Unspecified nephritic syndrome with minor glomerular abnormality

N05.1 Unspecified nephritic syndrome with focal and segmental glomerular lesions

N05.2 Unspecified nephritic syndrome with diffuse membranous glomerulonephritis

- N05.3 Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
- N05.4 Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis
- N05.5 Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
- N05.6 Unspecified nephritic syndrome with dense deposit disease

N05.7 Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis

N05.8 Unspecified nephritic syndrome with other morphologic changes

N05.9 Unspecified nephritic syndrome with unspecified morphologic changes

- N06.0 Isolated proteinuria with minor glomerular abnormality
- N06.1 Isolated proteinuria with focal and segmental glomerular lesions

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 100 of 148 N06.2 Isolated proteinuria with diffuse membranous glomerulonephritis

N06.3 Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis

- N06.4 Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis
- N06.5 Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis
- N06.6 Isolated proteinuria with dense deposit disease
- N06.7 Isolated proteinuria with diffuse crescentic glomerulonephritis
- N06.8 Isolated proteinuria with other morphologic lesion
- N06.9 Isolated proteinuria with unspecified morphologic lesion
- N07.0 Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality
- N07.1 Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions
- N07.2 Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis
- N07.3 Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis
- N07.4 Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis
- N07.5 Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis
- N07.6 Hereditary nephropathy, not elsewhere classified with dense deposit disease
- N07.7 Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis
- N07.8 Hereditary nephropathy, not elsewhere classified with other morphologic lesions
- N07.9 Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions

#### PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 101 of 148

- N08 Glomerular disorders in diseases classified elsewhere
- N10 Acute pyelonephritis
- N11.0 Nonobstructive reflux-associated chronic pyelonephritis
- N11.1 Chronic obstructive pyelonephritis
- N11.8 Other chronic tubulo-interstitial nephritis
- N11.9 Chronic tubulo-interstitial nephritis, unspecified
- N12 Tubulo-interstitial nephritis, not specified as acute or chronic
- N13.0 Hydronephrosis with ureteropelvic junction obstruction
- N13.1 Hydronephrosis with ureteral stricture, not elsewhere classified
- N13.2 Hydronephrosis with renal and ureteral calculous obstruction
- N13.30 Unspecified hydronephrosis
- N13.39 Other hydronephrosis
- N13.4 Hydroureter
- N13.5 Crossing vessel and stricture of ureter without hydronephrosis
- N13.6 Pyonephrosis
- N13.70 Vesicoureteral-reflux, unspecified
- N13.71 Vesicoureteral-reflux without reflux nephropathy
- N13.721 Vesicoureteral-reflux with reflux nephropathy without hydroureter, unilateral
- N13.722 Vesicoureteral-reflux with reflux nephropathy without hydroureter, bilateral
- N13.729 Vesicoureteral-reflux with reflux nephropathy without hydroureter, unspecified
- N13.731 Vesicoureteral-reflux with reflux nephropathy with hydroureter, unilateral

N13.732 Vesicoureteral-reflux with reflux nephropathy with hydroureter, bilateral

N13.739 Vesicoureteral-reflux with reflux nephropathy with hydroureter, unspecified

- N13.8 Other obstructive and reflux uropathy
- N13.9 Obstructive and reflux uropathy, unspecified
- N14.0 Analgesic nephropathy

N14.1 Nephropathy induced by other drugs, medicaments and biological substances

- N14.2 Nephropathy induced by unspecified drug, medicament or biological substance
- N14.3 Nephropathy induced by heavy metals
- N14.4 Toxic nephropathy, not elsewhere classified
- N15.0 Balkan nephropathy
- N15.1 Renal and perinephric abscess
- N15.8 Other specified renal tubulo-interstitial diseases
- N15.9 Renal tubulo-interstitial disease, unspecified
- N16 Renal tubulo-interstitial disorders in diseases classified elsewhere
- N17.0 Acute kidney failure with tubular necrosis
- N17.1 Acute kidney failure with acute cortical necrosis
- N17.2 Acute kidney failure with medullary necrosis
- N17.8 Other acute kidney failure
- N17.9 Acute kidney failure, unspecified
- N18.1 Chronic kidney disease, stage 1
- N18.2 Chronic kidney disease, stage 2 (mild)
- N18.3 Chronic kidney disease, stage 3 (moderate)

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 103 of 148

N18.4	Chronic kidney disease, stage 4 (severe)
N18.5	Chronic kidney disease, stage 5
N18.6	End stage renal disease
N18.9	Chronic kidney disease, unspecified
N19	Unspecified kidney failure
N20.0	Calculus of kidney
N20.1	Calculus of ureter
N20.2	Calculus of kidney with calculus of ureter
N20.9	Urinary calculus, unspecified
N23	Unspecified renal colic
N25.0	Renal osteodystrophy
N25.1	Nephrogenic diabetes insipidus
N25.81	Secondary hyperparathyroidism of renal origin
N25.89	Other disorders resulting from impaired renal tubular function
N25.9	Disorder resulting from impaired renal tubular function, unspecified
N26	Unspecified contracted kidney
N26.1	Atrophy of kidney (terminal)
N26.2	Page kidney
N26.9	Renal sclerosis, unspecified
N27.0	Small kidney, unilateral
N27.1	Small kidney, bilateral

- N27.9 Small kidney, unspecified
- N28.0 Ischemia and infarction of kidney
- N28.1 Cyst of kidney, acquired

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 104 of 148

- N28.81 Hypertrophy of kidney
- N28.82 Megaloureter
- N28.83 Nephroptosis
- N28.84 Pyelitis cystica
- N28.85 Pyeloureteritis cystica
- N28.86 Ureteritis cystica
- N28.89 Other specified disorders of kidney and ureter
- N28.9 Disorder of kidney and ureter, unspecified
- N29 Other disorders of kidney and ureter in diseases classified elsewhere

### 15.4.1.9. Liver Disorders

### 15.4.1.9.1. ICD-10-CM Codes

- K70.10 Alcoholic hepatitis without ascites
- K70.11 Alcoholic hepatitis with ascites
- K70.2 Alcoholic fibrosis and sclerosis of liver
- K70.30 Alcoholic cirrhosis of liver without ascites
- K70.31 Alcoholic cirrhosis of liver with ascites
- K70.40 Alcoholic hepatic failure without coma
- K70.41 Alcoholic hepatic failure with coma
- K70.9 Alcoholic liver disease, unspecified
- K71.0 Toxic liver disease with cholestasis
- K71.10 Toxic liver disease with hepatic necrosis, without coma
- K71.11 Toxic liver disease with hepatic necrosis, with coma
- K71.2 Toxic liver disease with acute hepatitis
- K71.3 Toxic liver disease with chronic persistent hepatitis

- K71.4 Toxic liver disease with chronic lobular hepatitis
- K71.50 Toxic liver disease with chronic active hepatitis without ascites
- K71.51 Toxic liver disease with chronic active hepatitis with ascites
- K71.6 Toxic liver disease with hepatitis, not elsewhere classified
- K71.7 Toxic liver disease with fibrosis and cirrhosis of liver
- K71.8 Toxic liver disease with other disorders of liver
- K71.9 Toxic liver disease, unspecified K72 Hepatic failure, not elsewhere classified Includes: fulminant hepatitis NEC, with hepatic failure
- K72.00 Acute and subacute hepatic failure without coma
- K72.01 Acute and subacute hepatic failure with coma
- K72.10 Chronic hepatic failure without coma
- K72.11 Chronic hepatic failure with coma
- K72.90 Hepatic failure, unspecified without coma
- K72.91 Hepatic failure, unspecified with coma
- K73.0 Chronic persistent hepatitis, not elsewhere classified
- K73.1 Chronic lobular hepatitis, not elsewhere classified
- K73.2 Chronic active hepatitis, not elsewhere classified
- K73.8 Other chronic hepatitis, not elsewhere classified
- K73.9 Chronic hepatitis, unspecified
- K74.0 Hepatic fibrosis
- K74.1 Hepatic sclerosis
- K74.2 Hepatic fibrosis with hepatic sclerosis
- K74.3 Primary biliary cirrhosis
- K74.4 Secondary biliary cirrhosis

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 106 of 148

- K74.5 Biliary cirrhosis, unspecified K74.60 Unspecified cirrhosis of liver K74.69 Other cirrhosis of liver Abscess of liver K75.0 K75.1 Phlebitis of portal vein K75.2 Nonspecific reactive hepatitis Granulomatous hepatitis, not elsewhere classified K75.3 K75.4 Autoimmune hepatitis K75.81 Nonalcoholic steatohepatitis (NASH) K75.89 Other specified inflammatory liver diseases K75.9 Inflammatory liver disease, unspecified K76.0 Fatty (change of) liver, not elsewhere classified K76.1 Chronic passive congestion of liver K76.2 Central hemorrhagic necrosis of liver Infarction of liver K76.3 K76.4 **Peliosis** hepatis
  - K76.5 Hepatic veno-occlusive disease
  - K76.6 Portal hypertension
  - K76.7 Hepatorenal syndrome
  - K76.81 Hepatopulmonary syndrome
  - K76.89 Other specified diseases of liver
  - K76.9 Liver disease, unspecified
  - K77 Liver disorders in diseases classified elsewhere

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 107 of 148

### 15.4.1.10. Neurological or Neurodevelopmental Conditions

### 15.4.1.10.1. ICD-10-CM Codes

- F70 Mild intellectual disabilities
- F71 Moderate intellectual disabilities
- F72 Severe intellectual disabilities
- F73 Profound intellectual disabilities
- F78 Other intellectual disabilities
- F79 Unspecified intellectual disabilities
- F80.0 Phonological disorder
- F80.1 Expressive language disorder
- F80.2 Mixed receptive-expressive language disorder
- F80.4 Speech and language development delay due to hearing loss
- F80.81 Childhood onset fluency disorder
- F80.82 Social pragmatic communication disorder
- F80.89 Other developmental disorders of speech and language
- F80.9 Developmental disorder of speech and language, unspecified
- F81.0 Specific reading disorder
- F81.2 Mathematics disorder
- F81.81 Disorder of written expression
- F81.89 Other developmental disorders of scholastic skills
- F81.9 Developmental disorder of scholastic skills, unspecified
- F82 Specific developmental disorder of motor function
- F84.0 Autistic disorder
- F84.2 Rett's syndrome

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 108 of 148
F84.3	Other childhood disintegrative disorder
F84.5	Asperger's syndrome
F84.8	Other pervasive developmental disorders
F84.9	Pervasive developmental disorder, unspecified
F89	Unspecified disorder of psychological development

## 15.4.1.11. Malignant Neoplasms

## 15.4.1.11.1. ICD-10-CM Codes

- C00-C14 Malignant neoplasms of lip, oral cavity and pharynx
- C15-C26 Malignant neoplasms of digestive organs
- C30-C39 Malignant neoplasms of respiratory and intrathoracic organs
- C40-C41 Malignant neoplasms of bone and articular cartilage
- C43-C44 Melanoma and other malignant neoplasms of skin
- C45-C49 Malignant neoplasms of mesothelial and soft tissue
- C50 Malignant neoplasms of breast
- C51-C58 Malignant neoplasms of female genital organs
- C60-C63 Malignant neoplasms of male genital organs
- C64-C68 Malignant neoplasms of urinary tract
- C69-C72 Malignant neoplasms of eye, brain and other parts of central nervous system
- C73-C75 Malignant neoplasms of thyroid and other endocrine glands
- C7A Malignant neuroendocrine tumors
- C7B Secondary neuroendocrine tumors
- C76-C80 Malignant neoplasms of ill-defined, other secondary and unspecified sites
- C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissue

## 15.4.1.12. Obesity

#### 15.4.1.12.1. ICD-10-CM Codes

E66.0	Obesity due to excess calories
E66.01	Morbid (severe) obesity due to excess calories
E66.09	Other obesity due to excess calories
E66.1	Drug-induced obesity
E66.2	Morbid (severe) obesity with alveolar hypoventilation
E66.8	Other obesity
E66.9	Obesity, unspecified

## 15.4.1.13. Type 2 Diabetes

## 15.4.1.13.1. ICD-10-CM Codes

E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic
	hyperglycemic-hyperosmolar coma (NKHHC)

- E11.01 Type 2 diabetes mellitus with hyperosmolarity with coma
- E11.10 Type 2 diabetes mellitus with ketoacidosis without coma
- E11.11 Type 2 diabetes mellitus with ketoacidosis with coma
- E11.21 Type 2 diabetes mellitus with diabetic nephropathy
- E11.22 Type 2 diabetes mellitus with diabetic chronic kidney disease
- E11.29 Type 2 diabetes mellitus with other diabetic kidney complication
- E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
- E11.319 Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
- E11.321 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
- E11.329 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 110 of 148

- Type 2 diabetes mellitus with moderate nonproliferative diabetic E11.331 retinopathy with macular edema E11.339 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema E11.341 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema Type 2 diabetes mellitus with severe nonproliferative diabetic E11.349 retinopathy without macular edema Type 2 diabetes mellitus with proliferative diabetic retinopathy with E11.351 macular edema E11.352 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula Type 2 diabetes mellitus with proliferative diabetic retinopathy with E11.353 traction retinal detachment not involving the macula E11.354 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment E11.355 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy E11.359 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema E11.36 Type 2 diabetes mellitus with diabetic cataract E11.37 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment E11.39 Type 2 diabetes mellitus with other diabetic ophthalmic complication E11.40 Type 2 diabetes mellitus with diabetic neuropathy, unspecified
  - E11.41 Type 2 diabetes mellitus with diabetic mononeuropathy
  - E11.42 Type 2 diabetes mellitus with diabetic polyneuropathy
  - E11.43 Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy
  - E11.44 Type 2 diabetes mellitus with diabetic amyotrophy

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 111 of 148 E11.49 Type 2 diabetes mellitus with other diabetic neurological complication

E11.51 Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene

E11.52 Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene

- E11.59 Type 2 diabetes mellitus with other circulatory complications
- E11.610 Type 2 diabetes mellitus with diabetic neuropathic arthropathy
- E11.618 Type 2 diabetes mellitus with other diabetic arthropathy
- E11.620 Type 2 diabetes mellitus with diabetic dermatitis
- E11.621 Type 2 diabetes mellitus with foot ulcer
- E11.628 Type 2 diabetes mellitus with other skin complications
- E11.630 Type 2 diabetes mellitus with periodontal disease
- E11.638 Type 2 diabetes mellitus with other oral complications
- E11.641 Type 2 diabetes mellitus with hypoglycemia with coma
- E11.649 Type 2 diabetes mellitus with hypoglycemia without coma
- E11.65 Type 2 diabetes mellitus with hyperglycemia
- E11.69 Type 2 diabetes mellitus with other specified complication
- E11.8 Type 2 diabetes mellitus with unspecified complications
- E11.9 Type 2 diabetes mellitus without complications

## 15.4.2. Medication History

## 15.4.2.1. Systemic Immunomodulators

The below list includes generic drug names classified by therapeutic use. All associated NDC codes will be utilized. Additional therapies may be added as they are approved.

## 15.4.2.1.1. Immunomodulators

## 15.4.2.1.1.1. Colony-Stimulating Factors

ancestim balugrastim

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 112 of 148 efbemalenograstim alfa empegfilgrastim filgrastim lenograstim lipegfilgrastim molgramostim pegfilgrastim pegteograstim sargramostim

#### 15.4.2.1.1.2. Interferons

albinterferon alfa-2b cepeginterferon alfa-2b interferon alfa natural interferon alfa-2a interferon alfa-2b interferon alfacon-1 interferon alfa-n1 interferon beta natural interferon beta-1a interferon beta-1b interferon gamma peginterferon alfa-2a peginterferon alfa-2a, combinations peginterferon alfa-2b peginterferon alfa-2b, combinations peginterferon alfacon-2 peginterferon beta-1a ropeginterferon alfa-2b

## 15.4.2.1.1.3. Interleukins

aldesleukin oprelvekin

## 15.4.2.1.1.4. Other Immunostimulants

BCG vaccine cridanimod dasiprotimut-T elapegademase glatiramer acetate histamine dihydrochloride

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 113 of 148 immunocyanin lentinan melanoma vaccine mifamurtide pegademase pidotimod plerixafor polyinosinic:polycytidylic acid (poly I:C) poly ICLC roquinimex sipuleucel-T tasonermin thymopentin

## 15.4.2.1.2. Immunosuppresants

## 15.4.2.1.2.1. Selective Immunosuppressants

abatacept abetimus alefacept alemtuzumab anifrolumab antilymphocyte immunoglobulin (horse) antithymocyte immunoglobulin (rabbit) apremilast avacopan baricitinib begelomab belatacept belimumab belumosudil cladribine deucravacitinib eculizumab efalizumab efgartigimod alfa emapalumab everolimus filgotinib fingolimod gusperimus imlifidase inebilizumab

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 114 of 148 itacitinib leflunomide muromonab-CD3 mycophenolic acid natalizumab ocrelizumab ofatumumab ozanimod peficitinib pegcetacoplan ponesimod ravulizumab siponimod sirolimus sutimlimab teprotumumab teriflunomide tofacitinib ublituximab upadacitinib vedolizumab

## 15.4.2.1.2.2. Tumor Necrosis Factor Alpha (TNF-α) Inhibitors

adalimumab afelimomab certolizumab pegol etanercept golimumab infliximab opinercept

## 15.4.2.1.2.3. Interleukin Inhibitors

anakinra basiliximab bimekizumab briakinumab brodalumab canakinumab daclizumab guselkumab ixekizumab netakimab olokizumab

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 115 of 148

rilonacept risankizumab sarilumab satralizumab secukinumab siltuximab sirukumab spesolimab tildrakizumab tocilizumab ustekinumab

#### 15.4.2.1.2.4. Calcineurin Inhibitors

cyclosporine tacrolimus voclosporin

#### 15.4.2.1.2.5. Other Immunosuppresants

azathioprine darvadstrocel dimethyl fumarate diroximel fumarate lenalidomide methotrexate pirfenidone pomalidomide thalidomide

## 15.4.2.1.3. Chemotherapeutic Agents

## 15.4.2.1.3.1. Alkylating Agents

chlorambucil cisplatin cyclophosphamide

## 15.4.2.1.3.2. Antimetabolite Agents

5-fluorouracil 6-mercaptopurine cytarabine methotrexate

## 15.4.2.1.3.3. Antitumor Antibiotics

bleomycin doxorubicin mitomycin C

## 15.4.2.1.3.4. Mitotic Inhibitors

paclitaxel plant alkaloids (vinblastine, vincristine)

## 15.4.2.1.3.5. Topoisomerase Inhibitors

etoposide irinotecan opotecan

## 15.4.2.1.4. Myelosuppresive Agents

hydroxyurea

## 15.4.2.1.5. ICD-10-CM, CPT<sup>9</sup> and HCPCS Codes

In addition to NDC codes for the above, the following ICD-10, CPT and HCPCS codes will be used:

## ICD-10-CM:

T45.1***	Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs
Z79.6	Long term (current) use of immunomodulators and immunosuppressants
Z79.60	Long term (current) use of unspecified immunomodulators and immunosuppressants
Z79.61	Long term (current) use of immunomodulator (apremilast, immunomodulatory imide drug, lenalidomide, pomalidomide)
Z79.62	Long term (current) use of immunosuppressant
Z79.620	Long term (current) use of immunosuppressive biologic (adalimumab, etanercept, infliximab, monoclonal antibodies)

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 117 of 148

<sup>&</sup>lt;sup>9</sup> CPT copyright 2022 American Medical Association. All rights reserved.

	Z79.621	Long term (current) use of calcineurin inhibitor (cyclosporine, tacrolimus)
	Z79.622	Long term (current) use of Janus kinase inhibitor (tofacitinib)
	Z79.623	Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor (sirolimus)
	Z79.624	Long term (current) use of inhibitors of nucleotide synthesis (azathioprine, omycophenolate, purine synthesis (IMDH) inhibitors)
	Z79.63	Long term (current) use of chemotherapeutic agent
	Z79.630	Long term (current) use of alkylating agent (chlorambucil, cisplatin, cyclophosphamide)
	Z79.631	Long term (current) use of antimetabolite agent (5-fluorouracil, 6-mercaptopurine, cytarabine, methotrexate)
	Z79.632	Long term (current) use of antitumor antibiotic (bleomycin, doxorubicin, mitomycin C)
	Z79.633	Long term (current) use of mitotic inhibitor (paclitaxel, plant alkaloids, vinblastine, vincristine)
	Z79.634	Long term (current) use of topoisomerase inhibitor (etoposide, irinotecan, topotecan)
	Z79.64 (hydroxyurea)	Long term (current) use of myelosuppressive agent
	Z79.69	Long term (current) use of other immunomodulators and immunosuppressants
<u>ICD-10-I</u>	<u>PCS:</u>	
	3E03302	Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
	3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
	3E04002	Introduction of High-dose Interleukin-2 into Central Vein, Open Approach

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 118 of 148

3E04003	Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach
3E04302	Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach
3E05002	Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
3E05302	Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
3E050WK	Introduction of Immunostimulator into Peripheral Artery, Open
3E050WL Open	Introduction of Immunosuppressive into Peripheral Artery,
3E053WL	Introduction of Immunosuppressive into Peripheral Artery, Percutaneous
3E053WL	Introduction of Immunosuppressive into Peripheral Artery, Percutaneous
3E060WK	Introduction of Immunostimulator into Central Artery, Open
3E060WL	Introduction of Immunosuppressive into Central Artery, Open
3E063WK Percutaneous	Introduction of Immunostimulator into Central Artery,
3E063WL Percutaneous	Introduction of Immunosuppressive into Central Artery,
XW01397	Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW033C6	Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H5	Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033L6	Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
CT24-WI-GL02-RF02 5.0 Non-I	PFIZER CONFIDENTIAL nterventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 119 of 148

XW033L7	Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033M7	Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03308	Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW03398	Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW04308	Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
XW04398	Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
XW043G5	Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043H5	Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043L6	Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
80145	Adalimumab
80158	Cyclosporine

<sup>&</sup>lt;sup>10</sup> CPT copyright 2022 American Medical Association. All rights reserved.

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 120 of 148

**CPT<sup>10</sup>** 

	80169	Everolimus
	80180	Mycophenolate (mycophenolic acid)
	80193	Leflunomide
	80195	Sirolimus
	80197	Tacrolimus
	80180	Mycophenolate (mycophenolic acid)
	80204	Methotrexate
	80230	Infliximab
	80280	Vedolizumab
	90585	Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use
	90586	Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use
HCPCS		
	J0129	Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
	J0135	Injection, adalimumab, 20 mg
	S0176	Hydroxyurea, oral, 500 mg
	J0215	Injection, alefacept, 0.5 mg
	J0202	Injection, alemtuzumab, 1 mg
	J0480	Injection, basiliximab, 20 mg
	J0485	Injection, belatacept, 1 mg
	J0490	Injection, belimumab, 10 mg
	J0491	Injection, anifrolumab-fnia, 1 mg
	J0638	Injection, canakinumab, 1 mg

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 121 of 148

J0717	Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
J1300	Injection, eculizumab, 10 mg
J1302	Injection, sutimlimab-jome, 10 mg
J1303	Injection, ravulizumab-cwvz, 10 mg
J1438	Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
J1442	Injection, filgrastim (G-CSF), excludes biosimilars, 1 mcg
J1447	Injection, tbo-filgrastim, 1 mcg
J1449	Injection, eflapegrastim-xnst, 0.1 mg
J1595	Injection, glatiramer acetate, 20 mg
J1602	Injection, golimumab, 1 mg, for intravenous use
J1628	Injection, guselkumab, 1 mg
J1745	Injection, infliximab, excludes biosimilar, 10 mg
J1747	Injection, spesolimab-sbzo, 1 mg
J1823	Injection, inebilizumab-cdon, 1 mg
J1826	Injection, interferon beta-1a, 30 mcg
J1830	Injection interferon beta-1b, 0.25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
J2323	Injection, natalizumab, 1 mg
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg
J2329	Injection, ublituximab-xiiy, 1mg
J2350	Injection, ocrelizumab, 1 mg
J2355	Injection, oprelvekin, 5 mg

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 122 of 148

J2504	Injection, pegademase bovine, 25 IU
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
J2562	Injection, plerixafor, 1 mg
J2781	Injection, pegcetacoplan, intravitreal, 1 mg
J2793	Injection, rilonacept, 1 mg
J2820	Injection, sargramostim (GM-CSF), 50 mcg
J2860	Injection, siltuximab, 10 mg
J3241	Injection, teprotumumab-trbw, 10 mg
J3245 mg	Injection, tildrakizumab, 1 mg J3380 Injection, vedolizumab, 1
J3262	Injection, tocilizumab, 1 mg
J3357	Ustekinumab, for subcutaneous injection, 1 mg
J3358	Ustekinumab, for intravenous injection, 1 mg
J7500-J7599:	Immunosuppressive drugs
J8560	Etoposide, oral, 50 mg
J8610	Methotrexate, oral, 2.5 mg
J9000	Injection, doxorubicin HCl, 10 mg
J9015	Injection, aldesleukin, per single use vial
J9030	BCG live intravesical instillation, 1 mg
J9037	Injection, belantamab mafodotin-blmf, 0.5 mg
J9040	Injection, bleomycin sulfate, 15 units
J9060	Injection, cisplatin, powder or solution, 10 mg
J9065 mg	Injection, cladribine, per 1 mg J9047 Injection, carfilzomib, 1
J9070	Cyclophosphamide, 100 mg

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 123 of 148

J9071	Injection, cyclophosphamide, (AuroMedics), 5 mg
J9098	Injection, cytarabine liposome, 10 mg
J9100	Injection, cytarabine, 100 mg
J9145	Injection, daratumumab, 10 mg
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9153 cytarabine	Injection, liposomal, 1 mg daunorubicin and 2.27 mg
J9176	Injection, elotuzumab, 1 mg
J9181	Injection, etoposide, 10 mg
J9190	Injection, fluorouracil, 500 mg
J9205	Injection, irinotecan liposome, 1 mg
J9206	Injection, irinotecan, 20 mg
J9210	Injection, emapalumab-lzsg, 1 mg
J9212	Injection, interferon alfacon-1, recombinant, 1 mcg
J9213	Injection, interferon, alfa-2a, recombinant, 3 million units
J9214	Injection, interferon, alfa-2b, recombinant, 1 million units
J9215 250,000 IU	Injection, interferon, alfa-N3, (human leukocyte derived),
J9216	Injection, interferon, gamma 1-b, 3 million units
J9247	Injection, melphalan flufenamide, 1 mg
J9250	Methotrexate sodium, 5 mg
J9259	Injection, paclitaxel protein-bound particles (American Regent) not therapeutically equivalent to J9264, 1 mg
J9260	Methotrexate sodium, 50 mg
J9264	Injection, paclitaxel protein-bound particles, 1 mg

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 124 of 148

J9267	Injection, paclitaxel, 1 mg
J9302	Injection, ofatumumab, 10 mg
J9331	Injection, sirolimus protein-bound particles, 1 mg
J9332	Injection, efgartigimod alfa-fcab, 2 mg
J9360	Injection, vinblastine sulfate, 1 mg
J9370	Vincristine sulfate, 1 mg
J9371	Injection, vincristine sulfate liposome, 1 mg
J9380	Injection, teclistamab-cqyv, 0.5 mg
M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation
M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal
Q0510	Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
Q2043	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion
Q2049 mg	Injection, doxorubicin HCl, liposomal, imported Lipodox, 10
Q2050 10 mg	Injection, doxorubicin HCl, liposomal, not otherwise specified,

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 125 of 148

Q2056	Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q2055	Idecabtagene vicleucel, up to 460 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q3027	Injection, interferon beta-1a, 1 mcg for intramuscular use
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use
Q5101	Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg
Q5108	Injection, pegfilgrastim-jmdb (Fulphila), biosimilar, 0.5 mg
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg Q5121 Injection, infliximab-axxq, biosimilar, (AVSOLA), 10 mg
Q5110	Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 mcg
Q5111	Injection, pegfilgrastim-cbqv (Udenyca), biosimilar, 0.5 mg
Q5120 mg	Injection, pegfilgrastim-bmez (ZIEXTENZO), biosimilar, 0.5
Q5122	Injection, pegfilgrastim-apgf (Nyvepria), biosimilar, 0.5 mg
Q5125	Injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg
Q5127	Injection, pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg
Q5130	Injection, pegfilgrastim-pbbk (Fylnetra), biosimilar, 0.5 mg
Q5131	Injection, adalimumab-aacf (Idacio), biosimilar, 20 mg
S0145	Injection, PEGylated interferon alfa-2A, 180 mcg per ml
S0148	Injection, PEGylated interferon alfa-2B, 10 mcg
S0172	Chlorambucil, oral, 2 mg

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 126 of 148

## 15.4.2.2. Corticosteroids

The below list includes generic drug names classified by therapeutic use. Codes for generic drugs are based on the Hierarchical Ingredient Code List (HICL) system proprietary to First Databank. All associated NDC codes will be utilized. Additional therapies may be added as they are approved.

## 15.4.2.2.1. Dermatological

#### 15.4.2.2.1.1. Weak

hydrocortisone methylprednisolone prednisolone

## 15.4.2.2.1.2. Moderately Potent

alclometasone clobetasone clocortolone desonide dexamethasone flumetasone fluocortin fluorometholone fluperolone fluperolone fluprednidene hydrocortisone buteprate hydrocortisone butyrate triamcinolone

## 15.4.2.2.1.3. Potent

amcinonide beclometasone betamethasone budesonide desoximetasone diflorasone diflucortolone difluprednate fluclorolone fludroxycortide fluocinolone acetonide fluocinonide fluocortolone fluticasone halometasone hydrocortisone aceponate

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 127 of 148 methylprednisolone aceponate mometasone prednicarbate ulobetasol

## 15.4.2.2.1.4. Very Potent

clobetasol halcinonide

## 15.4.2.2.2. Local Oral

dexamethasone hydrocortisone prednisolone triamcinolone

## 15.4.2.2.3. Intestinal Anti-Inflammatory

beclometasone betamethasone budesonide hydrocortisone prednisolone prednisone tixocortol beclometasone

## 15.4.2.2.4. Anti-Hemorrhoidal

betamethasone dexamethasone fluocinolone acetonide fluocinonide fluocortolone fluorometholone hydrocortisone prednisolone triamcinolone

## 15.4.2.2.5. Eye/Ear

alclometasone betamethasone clobetasone cortisone desonide dexamethasone fluocinolone acetonide fluorometholone

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 128 of 148 formocortal hydrocortisone loteprednol medrysone prednisolone rimexolone triamcinolone

#### 15.4.2.2.6. Systemic Corticosteroids

## 15.4.2.2.6.1. Mineralocorticoids

aldosterone desoxycortone fludrocortisone

## 15.4.2.2.6.2. Glucocorticoids

betamethasone cloprednol cortisone cortivazol deflazacort dexamethasone fluocortolone hydrocortisone meprednisone methylprednisolone paramethasone prednisolone prednisone prednylidene rimexolone triamcinolone

## 15.4.2.2.6.3. Anticorticosteroids

ketoconazole levoketoconazole osilodrostat trilostane

## 15.4.2.2.7. Other

adrenal cortex (porcine) prasterone (DHEA)

## 15.4.2.2.8. Full List

adrenal cortex (porcine)

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 129 of 148 alclometasone aldosterone amcinonide beclomethasone betamethasone budesonide ciclesonide clobetasol clobetasone clocortolone cloprednol cortisone cortivazol deflazacort desonide desoximetasone desoxycortone dexamethasone diflorasone diflucortolone difluprednate docusate sodium fluclorolone fludrocortisone fludroxycortide flumethasone flunisolide fluocinolone acetonide fluocinonide fluocortin fluocortolone fluorometholone fluperolone fluprednidene flurandrenolide fluticasone formocortal halcinonide halobetasol propionate

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 130 of 148 halometasone hydrocortisone ketoconazole levoketoconazole loteprednol medrysone meprednisone methylprednisolone mometasone osilodrostat paramethasone prasterone (DHEA) prednicarbate prednisolone prednisone prednylidene rimexolone tixocortol triamcinolone trilostane ulobetasol

## 15.4.2.2.9. ICD-10-CM, CPT<sup>11</sup> and HCPSC Codes

In addition to NDC codes for the above, the following ICD-10, CPT and HCPCS codes will be used:

## **ICD-10-CM**

	T38.0**	Poisoning by, adverse effect of and underdosing of glucocorticoids and synthetic analogues
	T50.0X*	Poisoning by, adverse effect of and underdosing of mineralocorticoids and their antagonists
<u>CPT</u>		
	4135F	Systemic corticosteroids Rx
	4136F	Systemic corticosteroids not Rx

<sup>11</sup> CPT copyright 2022 American Medical Association. All rights reserved.

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 131 of 148

4140F	Inhaled corticosteroids prescribed
4194F	Patient receiving =>10 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity (RA)

## **HCPCS**

G2113 Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity

J0702 Injection, betamethasone acetate 3mg and betamethasone sodium phosphate 3 mg

J1020	Injection, methylprednisolone acetate, 20 mg
J1030	Injection, methylprednisolone acetate, 40 mg
J1040	Injection, methylprednisolone acetate, 80 mg
J1094	Injection, dexamethasone acetate, 1 mg
J1095	Injection, dexamethasone 9%, intraocular, 1 mcg
J1096	Dexamethasone, lacrimal ophthalmic insert, 0.1 mg
J1100	Injection, dexamethasone sodium phosphate, 1 mg
J1700	Injection, hydrocortisone acetate, up to 25 mg
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg
J2650	Injection, prednisolone acetate, up to 1 ml
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg
J3299	Injection, triamcinolone acetonide (Xipere), 1 mg
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg
J3301 mg	Injection, triamcinolone acetonide, not otherwise specified, 10

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 132 of 148

J3302	Injection, triamcinolone diacetate, per 5 mg
J3303	Injection, triamcinolone hexacetonide, per 5 mg
J3304	Injection, triamcinolone acetonide, preservative-free, extended- release, microsphere formulation, 1 mg
J7311	Injection, fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg
J7313	Injection, fluocinolone acetonide, intravitreal implant (Iluvien), 0.01 mg
J7314 0.01 mg	Injection, fluocinolone acetonide, intravitreal implant (Yutiq),
J7402	Mometasone furoate sinus implant, (Sinuva), 10 mcg
J7509	Methylprednisolone, oral, per 4 mg
J7510	Prednisolone, oral, per 5 mg
J7512	Prednisone, immediate release or delayed release, oral, 1 mg
J7622	Beclomethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg
J7624	Betamethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg
J7626	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg
J7627	Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg
J7633	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg
J7634	Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 mg

J7637	Dexamethasone, inhalation solution, compounded product, administered through DME, concentrated form, per mg
J7638	Dexamethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg
J7641	Flunisolide, inhalation solution, compounded product, administered through DME, unit dose form, per mg
J7683	Triamcinolone, inhalation solution, compounded product, administered through DME, concentrated form, per mg
J7684	Triamcinolone, inhalation solution, compounded product, administered through DME, unit dose form, per mg
J8540	Dexamethasone, oral, 0.25 mg

#### 15.4.2.3. Antivirals

The below list includes generic drug names. All associated NDC codes will be utilized. Additional therapies may be added as they are approved.

#### 15.4.2.3.1. Topical

acyclovir docosanol penciclovir

## 15.4.2.3.2. Eye

fomivirsen ganciclovir idoxuridine trifluridine vidarabine

## 15.4.2.3.3. General Antivirals

acyclovir baloxavir marboxil brincidofovir cidofovir famciclovir foscarnet ganciclovir letermovir

maribavir oseltamivir peramivir ribavirin rimantadine tecovirimat valacyclovir zanamivir

## 15.4.2.3.4. HIV-Specific

abacavir amprenavir atazanavir cabotegravir cobicistat (in combination with others) darunavir delavirdine didanosine dolutegravir doravirine efavirenz elvitegravir emtricitabine enfuvirtide etravirine fosamprenavir fostemsavir indinavir lamivudine lopinavir maraviroc nelfinavir nevirapine raltegravir rilpivirine ritonavir saquinavir stavudine tenofovir

tipranavir

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 135 of 148

# zalcitabine

zidovudine

## 15.4.2.3.5. ICD-10-CM, CPT<sup>12</sup> and HCPCS Codes

In addition to NDC codes for the above, the following CPT and HCPCS codes will be used:

## ICD-10-PCS

	XW0DX38	Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
	XW0G738	Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8
	XW0H738	Introduction of Maribavir Anti-infective into Lower GI, Via Natural or ArtificialOpening, New Technology Group 8
<u>CPT</u>		
	4150F	Patient receiving antiviral treatment for Hepatitis C (HEP-C)
	4153F (HEP-C)	Combination peginterferon and ribavirin therapy prescribed
HCPCS		
	J0133	Injection, acyclovir, 5 mg
	J0739	Injection, cabotegravir, 1 mg
	J0740	Injection, cidofovir, 375 mg
	J0741	Injection, cabotegravir and rilpivirine, 2 mg/3 mg
	J1324	Injection, enfuvirtide, 1 mg
	J1452	Injection, fomivirsen sodium, intraocular, 1.65 mg
	J1455	Injection, foscarnet sodium, per 1,000 mg
	J1570	Injection, ganciclovir sodium, 500 mg

<sup>12</sup> CPT copyright 2022 American Medical Association. All rights reserved.

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 136 of 148

J1574	Injection, ganciclovir sodium (Exela) not therapeutically equivalent to J1570, 500 mg
J2547	Injection, peramivir, 1 mg
J3485	Injection, zidovudine, 10 mg
J7310	Ganciclovir, 4.5 mg, long-acting implant
S0104	Zidovudine, oral, 100 mg
S0137	Didanosine (ddI), 25 mg
S0140	Saquinavir, 200 mg

## 15.4.2.4. Antibiotics

The below list includes generic drug names, organized by therapeutic class codes and hierarchical ingredient codes developed by First Databank. Therapeutic class codes (THERSPEC) and the Hierarchical Ingredient Code List (HICL) are proprietary to First Databank. All associated NDC codes will be utilized. Additional therapies may be added as they are approved.

## 15.4.2.4.1. Vaginal

clindamycin metronidazole

## 15.4.2.4.2. Topical

bacitracin chloramphenicol clindamycin doxycycline erythromycin gentamicin meclocycline minocycline mupirocin neomycin ozenoxacin tetracycline

## 15.4.2.4.3. Eye and Ear

azithromycin bacitracin

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 137 of 148

besifloxacin cefuroxime chloramphenicol ciprofloxacin erythromycin gatifloxacin gentamicin levofloxacin moxifloxacin natamycin neomycin norfloxacin ofloxacin oxytetracycline polymyxin tetracycline tobramycin vancomycin

#### 15.4.2.4.4. Nose

mupirocin

## 15.4.2.4.5. Antitubercular

bedaquiline capreomycin cycloserine ethambutol isoniazid pretomanid pyrazinamide rifampin rifapentine

## 15.4.2.4.6. Broad Spectrum

#### 15.4.2.4.6.1. Penicillin Antibiotics

amoxicillin ampicillin bacampicillin carbenicillin cloxacillin

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 138 of 148 dicloxacillin mezlocillin nafcillin oxacillin penicillin piperacillin ticarcillin

## 15.4.2.4.6.2. Tetracycline Antibiotics

demeclocycline doxycycline eravacycline minocycline omadacycline oxytetracycline sarecycline tetracycline

## 15.4.2.4.6.3. Macrolide Antibiotics

azithromycin clarithromycin dirithromycin erythromycin fidaxomicin troleandomycin

## 15.4.2.4.6.4. Chloramphenicol Antibiotics and Derivatives

chloramphenicol

## 15.4.2.4.6.5. Aminoglycoside Antibiotics

amikacin gentamicin kanamycin neomycin netilmicin plazomicin streptomycin tobramycin

## 15.4.2.4.6.6. Aminocyclitol Antibiotics

spectinomycin

PFIZER CONFIDENTIAL CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 139 of 148

#### 15.4.2.4.6.7. Vancomycin Antibiotics and Derivatives

vancomycin

#### 15.4.2.4.6.8. Lincosamide Antibiotics

clindamycin lincomycin

#### 15.4.2.4.6.9. Antibiotics, Miscellaneous, Other

bacitracin novobiocin

#### 15.4.2.4.6.10. Streptogramin Antibiotics

dalfopristin quinupristin

## 15.4.2.4.6.11. Polymyxin Antibiotics and Derivatives

colistin polymyxin

## 15.4.2.4.6.12. Oxazolidinone Antibiotics

linezolid tedizolid

## 15.4.2.4.6.13. Quinolone Antibiotics

alatrofloxacin cinoxacin ciprofloxacin delafloxacin enoxacin gatifloxacin gemifloxacin grepafloxacin levofloxacin lomefloxacin moxifloxacin nalidixic acid norfloxacin ofloxacin sparfloxacin trovafloxacin

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 140 of 148

#### 15.4.2.4.6.14. Carbapenem Antibiotics (Thenamycins)

doripenem ertapenem imipenem meropenem

#### 15.4.2.4.6.15. Cephalosporin Antibiotics

cefaclor cefadroxil cefamandole cefazolin cefdinir cefditoren cefepime cefiderocol cefixime cefonicid cefoperazone cefotaxime cefotetan cefoxitin cefpodoxime cefprozil ceftazidime ceftibuten ceftizoxime ceftolozane ceftriaxone cefuroxime cephalexin cephalothin cephapirin cephradine loracarbef

## 15.4.2.4.6.16. Antifungal Antibiotics

amphotericin b anidulafungin caspofungin griseofulvin

ibrexafungerp micafungin nystatin rezafungin

#### 15.4.2.4.6.17. Ketolide Antibiotics

telithromycin

## 15.4.2.4.6.18. Rifamycins and Related Derivative Antibiotics

rifamycin rifaximin

## 15.4.2.4.6.19. Lipoglycopeptide Antibiotics

dalbavancin oritavancin telavancin

## 15.4.2.4.7. ICD-10-CM, CPT<sup>13</sup>, and HCPCS Codes

In addition to NDC codes for the above, the following CPT and HCPCS codes will be used:

## <u>ICD-10-CM</u>

	T36.***	Poisoning by, adverse effect of and underdosing of systemic antibiotics
<u>ICD-10-P</u>	<u>CS</u>	
	XW033R9	Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9
	XW043R9	Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
<u>CPT</u>		
	4045F	Appropriate empiric antibiotic prescribed (CAP), (EM)
	4046F	Documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or given intraoperatively (PERI 2)

<sup>13</sup> CPT copyright 2022 American Medical Association. All rights reserved.

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 142 of 148

	4047F	Documentation of order for prophylactic parenteral antibiotics to be given within 1 hour (if fluoroquinolone or vancomycin, 2
		hours) prior to surgical incision (or start of procedure when no incision is required) (PERI 2)
	4048F	Documentation that administration of prophylactic parenteral antibiotic was initiated within 1 hour (if fluoroquinolone or vancomycin, 2 hours) prior to surgical incision (or start of procedure when no incision is required) as ordered (PERI 2)
	4120F <sup>14</sup> BRONCH)	Antibiotic prescribed or dispensed (URI, PHAR), (A-
	80150	Amikacin
	80170	Gentamicin
	80200	Tobramycin
	80202	Vancomycin
HCPCS		
	C9462	Injection, delafloxacin, 1 mg
	G8710	Patient prescribed antibiotic
	G8711	Prescribed antibiotic on or within 3 days after the episode date
	G9498	Antibiotic regimen prescribed
	G9505	Antibiotic regimen prescribed within 10 days after onset of symptoms for documented medical reason
	G8916	Patient with preoperative order for IV antibiotic surgical site infection (SSI) prophylaxis, antibiotic initiated on time
	G9286 symptoms	Antibiotic regimen prescribed within 10 days after onset of
	G9315	Amoxicillin, with or without clavulanate, prescribed as a first line antibiotic at the time of diagnosis

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 143 of 148

<sup>&</sup>lt;sup>14</sup> CPT copyright 2022 American Medical Association. All rights reserved.

G9712	Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, acute pharyngitis, acute tonsillitis, chronic sinusitis
J0120	Injection, tetracycline, up to 250 mg
J0121	Injection, omadacycline, 1 mg
J0122	Injection, eravacycline, 1 mg
J0200	Injection, alatrofloxacin mesylate, 100 mg
J0278	Injection, amikacin sulfate, 100 mg
J0285	Injection, amphotericin B, 50 mg
J0287	Injection, amphotericin B lipid complex, 10 mg
J0288	Injection, amphotericin B cholesteryl sulfate complex, 10 mg
J0289	Injection, amphotericin B liposome, 10 mg
J0290	Injection, ampicillin sodium, 500 mg
J0291	Injection, plazomicin, 5 mg
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 g
J0348	Injection, anidulafungin, 1 mg
J0349	Injection, rezafungin, 1 mg
J0456	Injection, azithromycin, 500 mg
J0558	Injection, penicillin G benzathine and penicillin G procaine, 100,000 units
J0561	Injection, penicillin G benzathine, 100,000 units
J0637	Injection, caspofungin acetate, 5 mg
J0689	Injection, cefazolin sodium (Baxter), not therapeutically equivalent to J0690, 500 mg
J0690	Injection, cefazolin sodium, 500 mg

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 144 of 148
J0692	Injection, cefepime HCl, 500 mg
J0694	Injection, cefoxitin sodium, 1 g
J0695	Injection, ceftolozane 50 mg and tazobactam 25 mg
J0696	Injection, ceftriaxone sodium, per 250 mg
J0697	Injection, sterile cefuroxime sodium, per 750 mg
J0698	Injection, cefotaxime sodium, per g
J0699	Injection, cefiderocol, 10 mg
J0701	Injection, cefepime HCl (Baxter), not therapeutically equivalent to Maxipime, 500 mg
J0703	Injection, cefepime HCl (B. Braun), not therapeutically equivalent to Maxipime, 500 mg
J0710	Injection, cephapirin sodium, up to 1 g
J0713	Injection, ceftazidime, per 500 mg
J0714	Injection, ceftazidime and avibactam, 0.5 g/0.125 g
J0715	Injection, ceftizoxime sodium, per 500 mg
J0720	Injection, chloramphenicol sodium succinate, up to 1 g
J0736	Injection, clindamycin phosphate, 300 mg
J0737	Injection, clindamycin phosphate (Baxter), not therapeutically equivalent to J0736, 300 mg
J0742	Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
J0743	Injection, cilastatin sodium; imipenem, per 250 mg
J0744	Injection, ciprofloxacin for intravenous infusion, 200 mg
J0875	Injection, dalbavancin, 5 mg
J0878	Injection, daptomycin, 1 mg
J1267	Injection, doripenem, 10 mg

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 145 of 148

J1335	Injection, ertapenem sodium, 500 mg
J1364	Injection, erythromycin lactobionate, per 500 mg
J1580	Injection, garamycin, gentamicin, up to 80 mg
J1836	Injection, metronidazole, 10 mg
J1840	Injection, kanamycin sulfate, up to 500 mg
J1850	Injection, kanamycin sulfate, up to 75 mg
J1890	Injection, cephalothin sodium, up to 1 g
J1956	Injection, levofloxacin, 250 mg
J2010	Injection, lincomycin HCl, up to 300 mg
J2020	Injection, linezolid, 200 mg
J2021	Injection, linezolid (Hospira) not therapeutically equivalent to J2020, 200 mg
J2184	Injection, meropenem (B. Braun) not therapeutically equivalent to J2185, 100 mg
J2185	Injection, meropenem, 100 mg
J2186	Injection, meropenem, vaborbactam, 10 mg/10 mg, (20 mg)
J2247	Injection, micafungin sodium (Par Pharm) not therapeutically equivalent to J2248, 1 mg
J2248	Injection, micafungin sodium, 1 mg
J2265	Injection, minocycline HCl, 1 mg
J2280	Injection, moxifloxacin, 100 mg
J2281	Injection, moxifloxacin (Fresenius Kabi) not therapeutically equivalent to J2280, 100 mg
J2406	Injection, oritavancin (Kimyrsa), 10 mg
J2407	Injection, oritavancin (Orbactiv), 10 mg
J2460	Injection, oxytetracycline HCl, up to 50 mg

PFIZER CONFIDENTIAL

J2510	Injection, penicillin G procaine, aqueous, up to 600,000 units
J2540	Injection, penicillin G potassium, up to 600,000 units
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 g/0.125 g (1.125 g)
J2700	Injection, oxacillin sodium, up to 250 mg
J2770	Injection, quinupristin/dalfopristin, 500 mg (150/350)
J3000	Injection, streptomycin, up to 1 g
J3090	Injection, tedizolid phosphate, 1 mg
J3095	Injection, telavancin, 10 mg
J3260	Injection, tobramycin sulfate, up to 80 mg
J3320	Injection, spectinomycin dihydrochloride, up to 2 g
J3370	Injection, vancomycin HCl, 500 mg
J3371	Injection, vancomycin HCl (Mylan) not therapeutically equivalent to J3370, 500 mg
J3372	Injection, vancomycin HCl (Xellia) not therapeutically equivalent to J3370, 500 mg
J7342	Instillation, ciprofloxacin otic suspension, 6 mg
J7682	Tobramycin, inhalation solution, FDA-approved final product, noncompounded, unit dose form, administered through DME, per 300 mg
J7685	Tobramycin, inhalation solution, compounded product, administered through DME, unit dose form, per 300 mg
Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 g
S0021	Injection, cefoperazone sodium, 1 g
S0032	Injection, nafcillin sodium, 2 g
S0034	Injection, ofloxacin, 400 mg
S0040	Injection, ticarcillin disodium and clavulanate potassium, 3.1 g

PFIZER CONFIDENTIAL

CT24-WI-GL02-RF02 5.0 Non-Interventional Study Protocol Template For Secondary Data Collection Study 01-Aug-2023 Page 147 of 148 S0074 Injection, cefotetan disodium, 500 mg

S0081 Injection, piperacillin sodium, 500 mg

## **ANNEX 3. ADDITIONAL INFORMATION**

Not applicable.

## **Document Approval Record**

Document Name:	C4591062_PROTOCOL AND STATISTICAL ANALYSIS PLAN_V1.0_ 12DEC2023		
Document Title:	C4591062_PROTOCOL AND STATISTICAL ANALYSIS PLAN_V1.0_ 12DEC2023		
Signed By:	Date(GMT)	Signing Capacity	
De Bernardi, Barbara	15-Dec-2023 21:26:09	EUQPPV Approval	
Asomaning, Kofi	16-Dec-2023 14:39:09	Final Approval	